FTR #1134 Bio-Psy-Op Apocalypse Now, Part 9: Covid-19 Updates

As indi­cat­ed by the title of the pro­gram, this broad­cast updates var­i­ous arti­cles and book excerpts con­cern­ing Covid-19.

A Dai­ly Mail Online [UK] arti­cle sets forth two bogus papers con­tend­ing that the SARS CoV‑2 virus was genet­i­cal­ly engi­neered by the Chi­nese as a bioweapon in a lab­o­ra­to­ry and that it “escaped.” Note the cham­pi­oning of one of the papers by a for­mer head of MI6 and the author­ship of the sec­ond by The Epoch Times, the paper of the Falun Gong cult. Linked to CIA, Steve Ban­non’s anti-Chi­na milieu and the Trump admin­is­tra­tion, the orga­ni­za­tion is a fas­cist mind con­trol cult dis­cussed in numer­ous shows, includ­ing FTR #‘s 1089 and 1090. 

1.–“A for­mer MI6 chief was yes­ter­day accused by Gov­ern­ment offi­cials of ped­dling ‘fan­ci­ful claims’ that coro­n­avirus was acci­den­tal­ly cre­at­ed in a Chi­nese lab­o­ra­to­ry. British secu­ri­ty agen­cies believe Covid-19 is not a man-made virus and is ‘high­ly like­ly’ to have occurred nat­u­ral­ly and spread to humans through ani­mals. And Health Sec­re­tary Matt Han­cock has said there is ‘no evi­dence’ to back up the the­o­ry that it orig­i­nat­ed in a lab­o­ra­to­ry. But Sir Richard Dearlove, who was head of the MI6 from 1999 to 2004, cit­ed a recent report claim­ing the dis­ease was acci­den­tal­ly man­u­fac­tured by Chi­nese sci­en­tists.
2.–“ ‘I do think that this start­ed as an acci­dent,’ Sir Richard told The Dai­ly Telegraph’s ‘Plan­et Nor­mal’ pod­cast. ‘It rais­es the issue: if Chi­na ever were to admit respon­si­bil­i­ty, does it pay repa­ra­tions? I think it will make every coun­try in the world rethink how it treats its rela­tion­ship with Chi­na.’ He added: ‘Look at the sto­ries... of attempts by the [Bei­jing] lead­er­ship to lock down any debate about the ori­gins of the pan­dem­ic and the way peo­ple have been arrest­ed or silenced.’ . . . . The paper – co-authored by Pro­fes­sor Angus Dal­gleish, a renowned oncol­o­gist and vac­cine researcher who works at St George’s Hos­pi­tal, Uni­ver­si­ty of Lon­don, and Birg­er Sorensen, a Nor­we­gian virol­o­gist – con­tains none of the stark alle­ga­tions that orig­i­nal­ly stunned its review­ers.
3..–“The ini­tial paper that trig­gered wild rumours failed strin­gent tests of ver­i­fi­ca­tion and is under­stood to have been reject­ed in April by emi­nent inter­na­tion­al jour­nals such as Nature and the Jour­nal of Virol­o­gy. Bio­med­ical experts from the Fran­cis Crick Insti­tute and Impe­r­i­al Col­lege Lon­don are said to have refut­ed its con­clu­sions. Then one of the paper’s co-authors, Dr John Fredrik Moxnes, chief sci­en­tif­ic advis­er to the Nor­we­gian mil­i­tary, asked for his name to be with­drawn. This week, after numer­ous rewrites, the paper was pub­lished by the Quar­ter­ly Review of Bio­physics Dis­cov­ery. And those orig­i­nal world-shak­ing con­clu­sions have now with­ered to innu­en­do. No accu­sa­tion of Chi­nese manip­u­la­tion appears. . . .”
4.–”. . . . Back in April, a slick­ly pro­duced inves­tiga­tive doc­u­men­tary, Track­ing Down The Ori­gin Of The Wuhan Coro­n­avirus, was released online. It claimed con­clu­sive proof that the Covid-19 virus had been cre­at­ed as a bio­log­i­cal ‘weapon of mass destruc­tion’ in a Chi­nese lab. . . .”
5.–“At first sight, it seemed a shock­ing­ly con­vinc­ing piece of jour­nal­ism. On behalf of this news­pa­per, I cross-checked every claim: The experts it cit­ed and the fac­tu­al evi­dence unearthed. I also researched the back­grounds of its mak­ers. I then approached some of the world’s best inde­pen­dent sci­en­tif­ic author­i­ties to ask their opin­ion. They all agreed – this entic­ing­ly spicy sto­ry just did­n’t stand up.”
6.–“It had been pro­duced by a US based anti-Chi­nese gov­ern­ment media organ­i­sa­tion called the Epoch Times. Its ‘experts’ were vet­er­an hard-Right­ists. Most damn­ing­ly, its sci­en­tif­ic ‘facts’ were twist­ed out of shape.So much, then, for the Chi­nese-man­u­fac­tured coro­n­avirus con­spir­a­cy . . .”

Steve Ban­non is at the epi­cen­ter of the anti-Chi­na effort and–to no one’s surprise–never real­ly left the Trump White House.

When assess­ing Ban­non as a polit­i­cal ani­mal, one should nev­er for­get that among the impor­tant ide­o­log­i­cal influ­ences on him is Julius Evola, an Ital­ian fas­cist who found Mus­soli­ni too mod­er­ate and ulti­mate­ly took his cues from the Nazi SS, who were financ­ing his work by the end of World War II.

” . . . . Don­ald Trump’s light­ning-rod 2016 cam­paign boss and for­mer White House chief strate­gist who was ban­ished from the West Wing in 2017 has qui­et­ly crept back into 1600 Penn­syl­va­nia Ave., reestab­lish­ing ties to staffers, par­tic­u­lar­ly with regard to his pet issues of Chi­na and immi­gra­tion. . . . Anoth­er for­mer admin­is­tra­tion offi­cial told The Post that Ban­non nev­er real­ly left the White House after he was fired, main­tain­ing con­tacts and keep­ing up reg­u­lar chan­nels of com­mu­ni­ca­tions with offi­cials there. . . .”

In addi­tion, as dis­cussed in FTR #‘s 1111 and 1112, Ban­non is part of a net­work that includes J. Kyle Bass and Tom­my Hicks, Jr. This nexus involves asym­met­ri­cal invest­ing with regard to the Hong Kong and Chi­nese economies and the inter-agency gov­ern­men­tal net­works involved in both overt and covert anti-Chi­na poli­cies imple­ment­ed by Team Trump. As will be seen below, they also are net­work­ing with the mis-named “Sci­en­tists to Stop Covid-19.” In that regard, they are also help­ing steer pol­i­cy that con­trols devel­op­ment of treat­ment and vac­cines for Covid-19. The man­age­ment of drug and vac­cine devel­op­ment, in turn, dou­bles back to mar­ket-dri­ving invest­ment dynam­ics.

An inter­est­ing sum­ma­tion of char­ac­ter­is­tics of a “delib­er­ate” epi­dem­ic are eval­u­at­ed against the find­ing that New York City was the epi­cen­ter of the U.S. Covid-19 out­break: 

Bit­ten: The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons by Kris New­by; Harper­Collins [HC]; Copy­right 2019 by Kris New­by; ISBN 9780062896728; p. 185.

Poten­tial epi­demi­o­log­i­cal clues to a delib­er­ate epi­dem­ic:

Clue no. 1–A high­ly unusu­al event with large num­bers of casu­al­ties: Check!

Clue no. 2–Higher mor­bid­i­ty or mor­tal­i­ty than is expect­ed. Check!

Clue no. 3–Uncommon dis­ease. Check!

Clue no. 4–Point-source out­break. Check!

Clue no. 5–Multiple epi­demics. Check! (Glob­al pan­dem­ic)

                      –Z. F. Dem­bek, et al., “Dis­cern­ment Between Delib­er­ate and Nat­ur­al Infec­tious Dis­ease Out­breaks”

The pre­vail­ing view of the Covid-19 out­break con­tends that the Amer­i­can out­break spread out­ward from New York City. The strain of SARS CoV‑2 that appeared in New York came, in turn, from Europe. 

This does­n’t make sense. There were con­firmed cas­es of the virus on the West Coast that did not come from New York. A Euro­pean strain of the virus trans­mit­ted to New York City would have come in via air. In such an event, there would have been a well-doc­u­ment­ed out­break of Covid-19 among flight atten­dants, who oper­ate in close con­tact with pas­sen­gers in cramped cir­cum­stances, as well as expe­ri­enc­ing jet lag, which com­pro­mis­es the immune sys­tem.

Next, we review an aspect of the 2001 anthrax attacks. We high­light­ed the 2001 anthrax attacks in con­nec­tion with the Covid-19 out­break in New York City in FTR #1128.

We note that the Anthrax attacks appear to have oper­at­ed in over­lap­ping con­texts, includ­ing jus­ti­fi­ca­tion for the war in Iraq. 

The 2001 anthrax attacks appear to have served as a provo­ca­tion that jus­ti­fied a ten-fold increase in spend­ing for bio­log­i­cal war­fare devel­op­ment. The num­ber of BSL‑4 labs (hav­ing dual civil­ian and mil­i­tary use) increased from two in 2001, to a dozen in 2007.

This increase occurred while Don­ald Rums­feld was George W. Bush’s sec­re­tary of defense. He went to that posi­tion from being Chair­man of the Board of Direc­tors for Gilead Sci­ences, the man­u­fac­tur­er of remde­sivir.

We will delve into the pol­i­tics of the anthrax attacks in the future.

In the con­text of the above arti­cle, note that the Nation­al Insti­tutes of Health have also part­nered with CIA and the Pen­ta­gon, as under­scored by an arti­cle about a BSL‑4 lab at Boston Uni­ver­si­ty. Note that Europe and the U.S. have twelve BSL4 labs apiece. Tai­wan has two. Chi­na has one:

1.–As the arti­cle notes, as of 2007, the U.S. had “more than a dozen” BSL4 labs–China com­mis­sioned its first as of 2017. a ten­fold increase in fund­ing for BSL4 labs occurred because of the anthrax attacks of 2001. Those attacks might be seen as some­thing of a provo­ca­tion, spurring a dra­mat­ic increase in “dual use” biowar­fare research, under the cov­er of “legit­i­mate” medical/scientific research. In FTR #1128, we hypoth­e­sized about the milieu of Stephen Hat­fill and apartheid-linked inter­ests as pos­si­ble authors of a vec­tor­ing of New York City with Sars COV2: ” . . . . Before the anthrax mail­ings of 2001, the Unit­ed States had just two BSL4 labs—both with­in the razor-wire con­fines of gov­ern­ment-owned cam­pus­es. Now, thanks to a ten­fold increase in funding—from $200 mil­lion in 2001 to $2 bil­lion in 2006—more than a dozen such facil­i­ties can be found at uni­ver­si­ties and pri­vate com­pa­nies across the coun­try. . . .”
2.–The Boston Uni­ver­si­ty lab exem­pli­fies the Pen­ta­gon and CIA pres­ence in BSL‑4 facil­i­ty “dual use”: ” . . . . But some sci­en­tists say that argu­ment obscures the true pur­pose of the cur­rent biode­fense boom: to study poten­tial bio­log­i­cal weapons. ‘The uni­ver­si­ty por­trays it as an emerg­ing infec­tious dis­ease lab,’ says David Ozonoff, a Boston Uni­ver­si­ty epi­demi­ol­o­gist whose office is right across the street from the new BSL4 facil­i­ty. ‘But they are talk­ing about study­ing things like small pox and inhala­tion anthrax, which pose no pub­lic health threat oth­er than as bioweapons.’ . . . The orig­i­nal NIH man­date for the lab indi­cat­ed that many groups—including the CIA and Depart­ment of Defense—would be allowed to use the lab for their own research, the nature of which BU might have lit­tle con­trol over. . . .”

Piv­ot­ing to dis­cus­sion and review of the polit­i­cal, finan­cial and cor­po­rate con­nec­tions to the devel­op­ment of med­i­c­i­nal treat­ments for, and vac­cines to pre­vent, Covid-19, we recap details rel­e­vant to the extra­or­di­nary tim­ing of a 4/29 announce­ment of favor­able results for a tri­al of remde­sivir. That announce­ment drove equi­ties mar­kets high­er and was ben­e­fi­cial to the stock of Gilead Sci­ences.

We present a Stat News arti­cle on the inter­nal delib­er­a­tions behind the deci­sions to mod­i­fy the NIAID study. Of par­tic­u­lar sig­nif­i­cance is the DSMB delib­er­a­tion. Note the time­line of the DSMB delib­er­a­tion, com­bined with the announce­ment on 4/29 that drove the mar­kets high­er.

1.–The deci­sion was made to cut it short before the ques­tion of remdesivir’s impact on mor­tal­i­ty could be answered: ” . . . .The Nation­al Insti­tute of Aller­gy and Infec­tious Dis­eases has described to STAT in new detail how it made its fate­ful deci­sion: to start giv­ing remde­sivir to patients who had been assigned to receive a place­bo in the study, essen­tial­ly lim­it­ing researchers’ abil­i­ty to col­lect more data about whether the drug saves lives — some­thing the study, called ACTT‑1, sug­gests but does not prove. In the tri­al, 8% of the par­tic­i­pants giv­en remde­sivir died, com­pared with 11.6% of the place­bo group, a dif­fer­ence that was not sta­tis­ti­cal­ly sig­nif­i­cant. A top NIAID offi­cial said he had no regrets about the deci­sion. ‘There cer­tain­ly was una­nim­i­ty with­in the insti­tute that this was the right thing to do,’ said H. Clif­ford Lane, NIAID’s clin­i­cal direc­tor. . . .”
2.–In addi­tion, patients sched­uled to receive place­bo received remde­sivir, instead. ” . . . . Steven Nis­sen, a vet­er­an tri­al­ist and car­di­ol­o­gist at the Cleve­land Clin­ic, dis­agreed that giv­ing place­bo patients remde­sivir was the right call. ‘I believe it is in society’s best inter­est to deter­mine whether remde­sivir can reduce mor­tal­i­ty, and with the release of this infor­ma­tion doing a place­bo-con­trolled tri­al to deter­mine if there is a mor­tal­i­ty ben­e­fit will be very dif­fi­cult,’ he said. ‘The ques­tion is: Was there a route, or is there a route, to deter­mine if the drug can pre­vent death?’ The deci­sion is ‘a lost oppor­tu­ni­ty,’ he said. . . .”
3.–Steven Nis­sen was not alone in his crit­i­cism of the NIAID’s deci­sion. ” . . . .Peter Bach, the direc­tor of the Cen­ter for Health Pol­i­cy and Out­comes at Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter, agreed with Nis­sen. ‘The core under­stand­ing of clin­i­cal research par­tic­i­pa­tion and clin­i­cal research con­duct is we run the tri­al rig­or­ous­ly to pro­vide the most accu­rate infor­ma­tion about the right treat­ment,’ he said. And that answer, he argued, should ide­al­ly have deter­mined whether remde­sivir saves lives. The rea­son we have shut our whole soci­ety down, Bach said, is not to pre­vent Covid-19 patients from spend­ing a few more days in the hos­pi­tal. It is to pre­vent patients from dying. ‘Mor­tal­i­ty is the right end­point,’ he said. . . .”
4.–Not only was the admin­is­tra­tion of remde­sivir instead of place­bo pri­or­i­tized, but the NIAID study itself was atten­u­at­ed! ” . . . . But the change in the study’s main goal also changed the way the study would be ana­lyzed. Now, the NIAID decid­ed, the analy­sis would be cal­cu­lat­ed when 400 patients out of the 1,063 patients the study enrolled had recov­ered. If remde­sivir turned out to be much more effec­tive than expect­ed, ‘inter­im’ analy­ses would be con­duct­ed at a third and two-thirds that number.The job of review­ing these analy­ses would fall to a com­mit­tee of out­side experts on what is known as an inde­pen­dent data and safe­ty mon­i­tor­ing board, or DSMB. . . .”
5.–The per­for­mance of the DSMB for the remde­sivir study is note­wor­thy: ” . . . . But the DSMB for the remde­sivir study did not ever meet for an inter­im effi­ca­cy analy­sis, Lane said. All patients had been enrolled by April 20. The data for a DSMB meet­ing was cut off on April 22. The DSMB met and, on April 27, it made a rec­om­men­da­tion to the NIAID. . . .”
The DSMB meet­ing on 4/27 deter­mined the switch from place­bo to remde­sivir. Of para­mount impor­tance is the fact that this was JUST BEFORE the 4/29 announce­ment that drove the mar­kets high­er and the same day on which key Trump aide–and for­mer Gilead Sci­ences lob­by­ist Joe Gro­gan resigned! ” . . . . . That deci­sion, Lane said, led the NIAID to con­clude that patients who had been giv­en place­bo should be offered remde­sivir, some­thing that start­ed hap­pen­ing after April 28. . . .”
6.–Dr. Ethan Weiss gave an accu­rate eval­u­a­tion of the NIAID study: ” . . . . ‘We’ve squan­dered an incred­i­ble oppor­tu­ni­ty to do good sci­ence,’ [Dr. Ethan] Weiss said. ‘If we could ever go back and do some­thing all over, it would be the infra­struc­ture to actu­al­ly learn some­thing. Because we’re not learn­ing enough.’ . . . .”

The remark­able han­dling of the NIAID study, the tim­ing of the announce­ment of the alto­geth­er lim­it­ed suc­cess of the atten­u­at­ed tri­al and the rise in equi­ties as a result of the announce­ment may be best under­stood in the con­text of the role played in Trump pan­dem­ic deci­sion-mak­ing by an elite group of bil­lion­aires and scientists–including con­vict­ed felon Michael Milken (the “junk bond king”).

1.–” . . . . Call­ing them­selves ‘Sci­en­tists to Stop COVID-19,’ the col­lec­tion of top researchers, bil­lion­aires and indus­try cap­tains will act as an ‘ad hoc review board’ for the tor­rent of coro­n­avirus research, ‘weed­ing out’ flawed data before it reach­es pol­i­cy­mak­ers, the Wall Street Jour­nal report­ed on Mon­day. They are also act­ing as a go-between for phar­ma­ceu­ti­cal com­pa­nies seek­ing to build a com­mu­ni­ca­tion chan­nel with Trump admin­is­tra­tion offi­cials. The group . . . . has advised Nick Ayers, an aide to Vice Pres­i­dent Mike Pence, as well as oth­er agency heads, in the past month. Pence is head­ing up the White House coro­n­avirus task force. . . .”
2.–” . . . The brainy bunch is led by Thomas Cahill, a 33-year-old doc­tor who became a ven­ture cap­i­tal­ist . . . . Cahill’s clout comes from build­ing con­nec­tions through his invest­ment firm, New­path Part­ners, with Sil­i­con Valley’s Peter Thiel, the founder of Pay­Pal, and bil­lion­aire busi­ness­men Jim Palot­ta and Michael Milken. . . .”

Note that Peter Thiel played a dom­i­nant role in bankrolling New­path Part­ners, and the oth­er finan­cial angel who ele­vat­ed Cahill–Brian Sheth–introduced him to Tom­my Hicks, Jr., the co-chair­man of the RNC. In FTR #‘s 1111 and 1112, we looked at Hicks’ net­work­ing with Steve Ban­non asso­ciate J. Kyle Bass, as well as his role in the inter-agency net­works dri­ving the anti-Chi­na effort.

” . . . . At the helm of the effort: The 33-year-old and very-much-under-the-radar ven­ture cap­i­tal­ist Tom Cahill, who leads life sci­ences-focused New­path Part­ners. Cahill com­plet­ed his M.D. and PhD at Duke Uni­ver­si­ty a mere two years ago before land­ing at blue-chip invest­ment firm Rap­tor Group through a friend. He went on to found New­path with some $125 mil­lion after impress­ing well-con­nect­ed names like ven­ture cap­i­tal­ist Peter Thiel and Vista Equi­ty Part­ners co-founder Bri­an Sheth. . . . It was through Sheth, for exam­ple, that Sci­en­tists to Stop Covid-19 con­nect­ed with the co-chair­man of the Repub­li­can Nation­al Com­mit­tee, Thomas Hicks Jr. . . .”

The fed­er­al gov­ern­men­t’s extreme focus on remde­sivir has been shaped, in large mea­sure, by the influ­ence of “Sci­en­tists to Stop COVID-19”:

1.–“Scientists to Stop Covid-19” is shep­herd­ing remde­sivir: ” . . . . Sci­en­tists to Stop COVID-19 rec­om­mends that in this phase, the U.S. Food and Drug Admin­is­tra­tion (FDA) should work to coor­di­nate with Gilead phar­ma­ceu­ti­cals to focus on expe­dit­ing the results of clin­i­cal tri­als of remde­sivir, a drug iden­ti­fied as a poten­tial treat­ment for COVID-19. The group also rec­om­mends admin­is­ter­ing dos­es of the drug to patients in an ear­ly stage of infec­tion, and notes remde­sivir will essen­tial­ly be a place­hold­er until a more effec­tive treat­ment is pro­duced.
2.–The group is doing so by atten­u­at­ing the reg­u­la­to­ry process for coro­n­avirus drugs: “Gov­ern­ment enti­ties and agen­cies appear to adhere to the rec­om­men­da­tions out­lined by the group, with the Jour­nal report­ing that the FDA and the Depart­ment of Vet­er­ans Affairs (VA) have imple­ment­ed some of the sug­ges­tions, name­ly relax­ing drug man­u­fac­tur­er reg­u­la­tions and require­ments for poten­tial coro­n­avirus treat­ment drugs. . . .”

We con­clude dis­cus­sion of the remde­sivir machi­na­tions with a piece about the tim­ing of the announce­ment of Grogan’s depar­ture.

” . . . . Gro­gan has served as the direc­tor of the White House Domes­tic Pol­i­cy Coun­cil since Feb­ru­ary 2019, over­see­ing a broad array of pol­i­cy issues includ­ing health care and reg­u­la­tion. . . . Gro­gan was one of the orig­i­nal mem­bers of the White House coro­n­avirus task force launched in late Jan­u­ary. . . . Gro­gan worked as a lob­by­ist for drug com­pa­ny Gilead Sci­ences before join­ing the Trump admin­is­tra­tion. . . .”

The depar­ture was announced in the Wall Street Jour­nal on the morn­ing of Wednes­day, April 29, the same day we got our first pub­lic reports of the NIAID clin­i­cal tri­al of remde­sivir that was pos­i­tive enough to show it short­ened the time to recov­ery and the same day the FDA grant­ed remde­sivir emer­gency use sta­tus. 

Note, again, the tim­ing of the DSM­B’s actions, as well as the influ­ence of “Sci­en­tists to Stop Covid-19.”

In FTR #1130, we not­ed that Mon­cef Slaoui–formerly in charge of prod­uct devel­op­ment for Moderna–was cho­sen to head Trump’s “Oper­a­tion Warp Speed.” He will be work­ing with Four-Star Gen­er­al Gus­tave Per­na, cho­sen by Chair­man of the Joint Chiefs of Staff Gen­er­al Mark Mil­ley.

Even after agree­ing to sell his Mod­er­na stock, Mon­cef Slaoui’s invest­ments raise alarm­ing questions–note that he is a “ven­ture cap­i­tal­ist” and a long­time for­mer exec­u­tive at Glaxo-Smithk­line:

The cir­cum­stances of his appoint­ment will per­mit him to avoid scruti­ny: ” . . . . In agree­ing to accept the posi­tion, Dr. Slaoui did not come on board as a gov­ern­ment employ­ee. Instead, he is on a con­tract, receiv­ing $1 for his ser­vice. That leaves him exempt from fed­er­al dis­clo­sure rules that would require him to list his out­side posi­tions, stock hold­ings and oth­er poten­tial con­flicts. And the con­tract posi­tion is not sub­ject to the same con­flict-of-inter­est laws and reg­u­la­tions that exec­u­tive branch employ­ees must fol­low. . . .”
He will retain a great deal of Glaxo-Smithk­line stock: ” . . . . He did not say how much his GSK shares were worth. When he left the com­pa­ny in 2017, he held about [500,000 in West­ern Print Edi­tion] 240,000 shares and share equiv­a­lents, accord­ing to the drug company’s annu­al report and an analy­sis by the exec­u­tive com­pen­sa­tion firm Equi­lar. . . .”
Fur­ther analy­sis of Slaoui’s posi­tion deep­ens con­cern about the integri­ty of the process: ” . . . . ‘This is basi­cal­ly absurd,’ said Vir­ginia Can­ter, who is chief ethics coun­sel for Cit­i­zens for Respon­si­bil­i­ty and Ethics in Wash­ing­ton. ‘It allows for no pub­lic scruti­ny of his con­flicts of inter­est.’ Ms. Can­ter also said fed­er­al law barred gov­ern­ment con­trac­tors from super­vis­ing gov­ern­ment employ­ees. . . . Ms. Can­ter, a for­mer ethics lawyer in the Oba­ma and Clin­ton admin­is­tra­tions, the Secu­ri­ties and Exchange Com­mis­sion and oth­er agen­cies, point­ed out that GSK’s vac­cine can­di­date with Sanofi could wind up com­pet­ing with oth­er man­u­fac­tur­ers vying for gov­ern­ment approval and sup­port. ‘If he retains stock in com­pa­nies that are invest­ing in the devel­op­ment of a vac­cine, and he’s involved in over­see­ing this process to select the safest vac­cine to com­bat Covid-19, regard­less of how won­der­ful a per­son he is, we can’t be con­fi­dent of the integri­ty of any process in which he is involved,’ Ms. Can­ter said.In addi­tion, his affil­i­a­tion with Medicxi could com­pli­cate mat­ters: Two of its investors are GSK and a divi­sion of John­son & John­son, which is also devel­op­ing a poten­tial vac­cine. . . .”

Next, we turn to Mod­er­na’s ani­mal tri­al for the mes­sen­ger RNA vac­cine it is devel­op­ing. There are sev­er­al con­sid­er­a­tions to be weighed in con­nec­tion with the Mod­er­na vac­cine.

1.–Again, the chair­man of Trump’s “Warp Speed” vac­cine devel­op­ment program–Moncef Slaoui–was in charge of Mod­er­na’s prod­uct devel­op­ment oper­a­tion.
2.–Moderna’s tri­al with mice was pos­i­tive with regard to gen­er­at­ing anti­body lev­els high enough to pre­vent ADE.
3.–Antibody Depen­dent Enhance­ment (ADE),  is a phe­nom­e­na where low lev­els of inef­fec­tive anti­bod­ies latch onto the virus and exac­er­bate an over­ac­tive immune response that leads to the dead­liest symp­toms likes cytokine-storms. This dan­ger was seen with SARS and attempts to cre­ate a SARS vac­cine so it’s a rea­son­able fear with SARS-CoV­‑2.
4.–The Phase III (human) tri­al is going to be start­ed in July, involv­ing 30,000 peo­ple. Alarm­ing­ly, those 30,000 peo­ple will all be receiv­ing the exact same dosage, 100 micro­grams, and that means the phase III tri­al won’t be test­ing sub-opti­mal dosages. The big Phase III tri­al won’t be test­ing for ADE in humans. 
5.–We may have a night­mare sit­u­a­tion where polit­i­cal pres­sure gives undo weight to ani­mal safe­ty results, leapfrog­ging over the neces­si­ty of test­ing for side effects. 
6.–The ani­mal tri­als have been severe­ly crit­i­cized: ” . . . . ‘This is the barest begin­ning of pre­lim­i­nary infor­ma­tion,’ said Dr. Gre­go­ry Poland, an immu­nol­o­gist and vac­cine researcher at the Mayo Clin­ic who has seen the paper, which has yet to under­go peer-review. Poland said the paper was incom­plete, dis­or­ga­nized and the num­bers of ani­mals test­ed were small. . . . Poland, who was not involved with the research, said the paper leaves out ‘impor­tant para­me­ters’ that could help sci­en­tists judge the work. . . .”
7.–We MIGHT cre­ate a vac­cine that pro­tects those who get a strong immune response while endan­ger­ing those with sub-pro­tec­tive responses–a “eugenic” vac­cine.
8.–The ani­mal tri­als have been severe­ly crit­i­cized: ” . . . . ‘This is the barest begin­ning of pre­lim­i­nary infor­ma­tion,’ said Dr. Gre­go­ry Poland, an immu­nol­o­gist and vac­cine researcher at the Mayo Clin­ic who has seen the paper, which has yet to under­go peer-review. Poland said the paper was incom­plete, dis­or­ga­nized and the num­bers of ani­mals test­ed were small. . . . Poland, who was not involved with the research, said the paper leaves out ‘impor­tant para­me­ters’ that could help sci­en­tists judge the work. . . .”
9.–The phase II clin­i­cal tri­als on humans are still under­way and won’t be com­plet­ed before Novem­ber.  Phase III is going to be get­ting under­way in July. The Human clin­i­cal tri­als are already under­way at the same time the ani­mal safe­ty tri­als have yet to be com­plet­ed.
10.–Side effects can take a while to man­i­fest.

We pro­vid­ed detailed crit­i­cal com­ments on Mod­er­na’s Phase I tri­al in FTR #1132.

We con­clude with a New York Times arti­cle sets forth a “Vac­cine Octo­ber Sur­prise” sce­nario for this fall.

” . . . . In a des­per­ate search for a boost, he could release a coro­n­avirus vac­cine that has not been shown to be safe and effec­tive as an Octo­ber sur­prise. Oct. 23, 2020, 9 a.m., with 10 days before the elec­tion, Fox New releas­es a poll show­ing Pres­i­dent Trump trail­ing Joe Biden by eight per­cent­age points. Oct. 23, 2020, 3 p.m., at a hasti­ly con­vened news con­fer­ence, Pres­i­dent Trump announces that the Food and Drug Admin­is­tra­tion has just issued an Emer­gency Use Autho­riza­tion for a coro­n­avirus vac­cine. Mr. Trump declares vic­to­ry over Covid-19, demands that all busi­ness­es reopen imme­di­ate­ly and pre­dicts a rapid eco­nom­ic recov­ery. Giv­en how this pres­i­dent has behaved, this incred­i­bly dan­ger­ous sce­nario is not far-fetched. In a des­per­ate search for a polit­i­cal boost, he could release a coro­n­avirus vac­cine before it had been thor­ough­ly test­ed and shown to be safe and effec­tive. . . .”

FTR #1133: The Plot to Kill King

In the after­math of the killing of George Floyd, there has been wall-to-wall cov­er­age of his mur­der and of the world-wide demon­stra­tions stem­ming from it. The advent of smart phone (with cam­eras) and the inter­net affords detailed and inti­mate expe­ri­ence of such an event.

How­ev­er, the orgias­tic cov­er­age of that event, the memo­r­i­al ser­vice led by FBI infor­mant and alleged [by the late War­ren Hinck­le] CIA oper­a­tive in Grena­da Al Sharp­ton stands in stark con­trast to the utter silence across the board on the cir­cum­stances of Dr. Mar­tin Luther King’s assas­si­na­tion.

On the fifti­eth anniver­sary of King’s mur­der, Mr. Emory did a twelve hour pro­gram about the cir­cum­stances of the assas­si­na­tion, repris­ing AFA #8 (done in 1985 on the 17th anniver­sary of the killing) and FTR #46, record­ed a decade lat­er and sup­ple­ment­ed on 4/3/2018.

Despite exhaus­tive and per­ilous research done by the likes of Dr. William F. Pep­per, 4/4/2018 was notable for the absence of sub­stan­tive dis­cus­sion of King’s mur­der.

The polit­i­cal and his­tor­i­cal sig­nif­i­cance of such an event was pre­sent­ed by Dr. Pep­per in his third book about the King assas­si­na­tion, The Plot to Kill King: ” . . . . . . . . When one is con­front­ed with the assas­si­na­tion of a major leader who per­son­i­fies the most trea­sured val­ues of the species and it becomes clear that those respon­si­ble for the mur­der are offi­cials of his own gov­ern­ment act­ing with the sanc­tion of those in the shad­ows who actu­al­ly rule, sure­ly one should strive to under­stand what that means now and for the future. In oth­er words, when the removal of a leader who has offend­ed pow­er­ful forces and spe­cial inter­ests in the Repub­lic takes on the sta­tus of an act of state, cit­i­zens must con­tem­plate what this reveals about their cul­ture and its civ­il and polit­i­cal sys­tems, their free­dom, the qual­i­ty and sta­tus of the rule of law, and their entire way of life. . . . ”

It seems that–for many–black lives mat­ter, but not Dr. King’s, appar­ent­ly, past a point.

Again, Dr. Pep­per not­ed that: ” . . . . cit­i­zens must con­tem­plate what this reveals about their cul­ture and its civ­il and polit­i­cal sys­tems, their free­dom, the qual­i­ty and sta­tus of the rule of law, and their entire way of life. . . . ”

In said con­tem­pla­tion, this pro­gram sup­ple­ments our pre­vi­ous work on the killing.

Although Dr. Pep­per repris­es the stun­ning infor­ma­tion he set forth in Orders to Kill in The Plot to Kill King, we will not reprise that here, in the inter­ests of time. (We do recap a short excerpt from Orders to Kill com­pris­ing an appar­ent evi­den­tiary trib­u­tary between King’s mur­der and the assas­si­na­tion of Robert F. Kennedy, which occurred two months lat­er.)

The bulk of the dis­cus­sion in this pro­gram is pre­sen­ta­tion and analy­sis of the polit­i­cal machin­ery in Mem­phis, Ten­nessee that engi­neered Dr. King’s mur­der. (Dis­cus­sion of the Spe­cial Forces team that was in Mem­phis as a back-up unit in case the civil­ian sniper missed King is detailed in FTR #46.)

In Pep­per’s inves­ti­ga­tion of King’s mur­der­ers, he detailed the appar­ent role of the late Rus­sell Lee Adkins, a mem­ber of the Dix­ie Mafia in Mem­phis, Ten­nessee. (The Dix­ie Mafia is dis­tinct from the Mafia, per se, that oper­at­ed in the South, although–as Pep­per makes clear–they worked with Mafiosi like New Orleans capo Car­los Mar­cel­lo and Mar­cel­lo asso­ciate Frank Lib­er­to, like Adkins, an oper­a­tor in Mem­phis.) 

His son Rus­sell Jr. took over exec­u­tive man­age­ment of the assas­si­na­tion machin­ery after his father’s death in 1967.

Note the coop­er­a­tion between the Ku Klux Klan and ele­ments of the Masons in Mem­phis. This should NOT be mis­un­der­stood as buy­ing into the myr­i­ad of anti-Mason­ic con­spir­a­cy the­o­ries which have pro­lif­er­at­ed on the Inter­net. The bulk of Freema­son­ry are what they rep­re­sent them­selves as being–civic activists and phil­an­thropists. The Third Reich planned to exter­mi­nate the Masons, along with the Jews and oth­ers.

That hav­ing been said, there have always been net­works with­in the Masons which, due to to their clan­des­tine oper­at­ing struc­ture, have been uti­lized for con­spir­a­to­r­i­al pur­pos­es. In these broad­casts, we have not­ed the P‑2 lodge of Licio Gel­li as one such enti­ty.

The Rus­sell Adkins Klan/Mason nexus is anoth­er. Note Rus­sell Sr.‘s son Ron Adkins depo­si­tion about the deci­sive influ­ence of this insti­tu­tion­al­ly racist enti­ty and its pow­er­ful oper­a­tional con­nec­tions:

1.–It dom­i­nat­ed Mem­phis munic­i­pal pol­i­tics empow­er­ing May­or Hen­ry Loeb and Fire and Police Com­mis­sion­er Frank Hol­lo­man, among oth­ers fig­ur­ing in the mur­der of King.

2.–The Adkins/Klan milieu had long-stand­ing oper­a­tional links with the FBI. Num­ber two man in the bureau at the time, as well as J. Edgar Hoover’s live-in lover, was close to Rus­sell Adkins and used him to dis­pense pay­ments to bureau oper­a­tives, includ­ing the Rev­erend Jesse Jack­son.

2.–The Adkins/Klan milieu net­worked with the Mafia, as stat­ed above.

3.–Ron Adkins, Rus­sell Sr.‘s son, deposed under oath that: ” . . . . Ron said that his father took him to his first lynch­ing when he was just six years old. . . .”

4.–The Adkins milieu was close to Dr. Breen Bland, whose alleged role in King’s death is dis­cussed below.

Next, we present the role of the Adkins machine as a con­duit for Hoover and Tol­son’s financ­ing for the escape of pat­sy-to-be James Earl Ray: ” . . . . . . . . [FBI offi­cial Clyde] Tol­son was a sub­stan­tial con­nec­tion for his [Ron­nie Adkins’] father . . . . Of par­tic­u­lar inter­est to this case is that he brought the mon­ey which was to be paid to Harold Swen­son, the War­den of the Mis­souri State prison, in Jef­fer­son City, Mis­souri, in order for him to arrange for the escape of James in 1967. At Hoover’s request, James had been pro­filed as a poten­tial scape­goat, although the nature of the crime was not revealed. Ron told us about this assign­ment because he was an actu­al observ­er. He saw the mon­ey being deliv­ered by Tol­son and then, at his father’s invi­ta­tion, he rode to the prison where the mon­ey was paid to Swen­son by his father. . . Ray (who was always kept in the dark about this arrange­ment) suc­cess­ful­ly escaped from prison on April 23, 1967, and then . . . was mon­i­tored, con­trolled . . . . and moved around until the plans for the assas­si­na­tion and his use were final­ized. . . . .”

In the run-up to the assas­si­na­tion of king: ” . . . . In ear­ly 1968, two work­ers, thir­ty-five-year-old Echole Cole and twen­ty-nine-year-old Robert Walk­er were lit­er­al­ly swal­lowed by a mal­func­tion­ing ‘garbage pack­er’ truck. We would lat­er learn this was a planned mur­der by the Dix­ie Mafia fam­i­ly of Rus­sell Adkins, in coor­di­na­tion with Mem­phis Police Depart­ment Direc­tor of Police and Fire Frank Hol­lo­man, in order to com­pel Dr. King to return to sup­port the strik­ers. . . .” 

Sworn depo­si­tions by Lenny Cur­tis (a cus­to­di­an for the Mem­phis Police Depart­ment) and Nathan Whit­lock, a Mem­phis police­man named Frank Strauss­er was the actu­al shoot­er select­ed to exe­cute King: ” . . . . On that day, he [Strauss­er] broke to take lunch with [MPD Cap­tain Earl] Clark, and when he returned he resumed fir­ing. When he left at around 3:30 p.m., he put the top down on the con­vert­ible, took off his pow­der blue shirt, and threw it over the rifle in the back­seat, leav­ing only his white T‑shirt on. He ruf­fled his hair and put on a pair of sun­glass­es. When he left, May­or Loeb, Hol­lo­man, and the oth­er vis­it­ing police offi­cers were still there. They had met in Lieu­tenant Bullard’s office. . . .”

After high­light­ing the alleged role of Frank Strauss­er as the actu­al assas­sin, we present the oper­a­tional sequence of events on the ground in Mem­phis, Ten­nessee. Again, note the ubiq­ui­tous pres­ence of the Adkins/Dixie Mafia/Klan machine in the pro­gres­sion of events. ” . . . . Also observed arriv­ing at the MPD fir­ing range build­ing where he met with the shoot­er and Earl Clark were Direc­tor Hol­lo­man and May­or Hen­ry Loeb. . . .”

Note, also, the roles of Jesse Jack­son and the Rev­erend Bil­ly Kyles in these maneu­vers. (As dis­cussed in FTR #1005, both were being paid by FBI offi­cial Clyde Tol­son, through the Adkins machine. Jack­son’s appar­ent role was to help secure Room 306 in the Lor­raine Motel, over­look­ing the pool and afford­ing a clear shot, as well as to maneu­ver the Invaders out of the area. (The Invaders were a local Black Pow­er group who were present for secu­ri­ty pur­pos­es.) Kyles was there to help lure King out onto the bal­cony for the kill shot.

After King was shot, he was tak­en to St. Joseph’s hos­pi­tal, where, again the influ­ence of the Adkins machine came into play: ” . . . . . . . . Ron Adkins Tyler, under oath, told me that Dr. Breen Bland, who, remem­ber was also the Adkins’ fam­i­ly doc­tor, was in fact, the head sur­geon at the hos­pi­tal. . . . He said he was present and over­heard con­ver­sa­tions between his father and Dr. Bland, and then, fol­low­ing his father’s death, between his broth­er (Rus­sell Junior), Police and Fire Direc­tor Frank Hol­lo­man, and Dr. Bland about the impor­tance of Dr. King being tak­en to St. Joseph’s if he was still alive. . . . Ron Adkins Tyler has no doubt that they were deter­mined to make cer­tain that Dr. King would nev­er leave the emer­gency room at St. Joseph’s Hos­pi­tal alive. Though he did not know the details of the final cause of death, it appears that he was cor­rect. . . .”

Next, we focus on events at St. Joseph’s Hos­pi­tal on 4/4/1968:

1.–Among those events ” . . . . was the large pres­ence of mil­i­tary intel­li­gence offi­cers who had tak­en up posi­tions in the hos­pi­tal well before the shot was fired. Accord­ing to Dr. Cause­way, who was on duty at the time, the mil­i­tary intel­li­gence offi­cers knew the names of all of the emer­gency room nurs­es and doc­tors on duty. . . .”

2.–The atten­tion giv­en to the grave­ly wound­ed Dr. King: ” . . . . He [Dr. Cause­way] observed that no con­sid­er­a­tion was giv­en to mov­ing the crit­i­cal­ly injured vic­tim to the oper­at­ing room and he saw no sur­gi­cal effort being made to save him. When he inquired about treat­ment, he was told that he was being treat­ed. . . .”

3.–According to sur­gi­cal aide Lula Mae Shel­by: ” . . . . there were many MPD offi­cers and army peo­ple milling about, in addi­tion to men in suits. . . . Dr. King was lying on a blood­ied gur­ney. She saw the huge hole in the low­er left side of his face, but heard one of the ER doc­tors say that he has a pulse. The ER doc­tors had per­formed a tra­cheoto­my and insert­ed a breath­ing tube. . . . in a while, the head of surgery (who appears to have been Dr. Breen Bland–the Adkins’ fam­i­ly doc­tor and col­lab­o­ra­tor dis­cussed ear­li­er) came into the emer­gency room with a cou­ple of men in suits and shout­ed at the staff work­ing on Dr. King, ‘Stop work­ing on the nig­ger and let him die. Now, all of you get out of here, right now. Every­body get out.’ . . . . as she was leav­ing, she heard three sounds of the men gath­er­ing or suck­ing up sali­va in their mouths–and then she heard two or three spit­ting sounds. This caused her, on the way out, to glance back over her shoul­der, and see that the breath­ing tube had been removed and Dr. Bland put a pil­low on and over the face of Dr. King. . . .”

After the mur­der, the above-men­tioned Lenny Cur­tis heard rumors about Frank Strauss­er being the assas­sin of King, as well as dis­cus­sion of Strauss­er being pres­sured to leave the MPD because of civ­il rights com­plaints being lodged against him.

Con­cerned that Cur­tis might dis­close infor­ma­tion about him to the FBI, Strauss­er con­front­ed him dur­ing a dri­ve and deliv­ered a warn­ing: ” . . . . ‘Lenny, you be care­ful now.’ The look he gave him was clear­ly threat­en­ing. . . .”

Fol­low­ing this inci­dent, Cur­tis expe­ri­enced strange, fright­en­ing things: ” . . . . . His gas was strange­ly turned on once when he was about to enter his house. He had lit a cig­a­rette, but as he opened the door he smelled gas and quick­ly put out the cig­a­rette. A strange Lin­coln was occa­sion­al­ly parked across the street from his apart­ment house. . . .  One morn­ing when the car was there, he got into his own car and quick­ly drove off, and the strange car pulled out and fol­lowed him. He man­aged to see the dri­ver. It was Strauss­er. At that time, new evi­dence in the case came up. He said that every time new evi­dence arose the offi­cer would pop up. He tried to move to a new house with­out notice but the land­lord of the new com­plex would report see­ing a man in the back of his house. When Lenny checked the area, he found a ‘tree stand,’ a V‑shaped stand where you could rest a rifle. When he put a stick in it, it focused on his kitchen and bath­room win­dows. He moved again, with­out notice. . . .”

Pep­per found Cur­tis to be inspir­ing, wait­ing until after his death in 2013 to come for­ward with his tes­ti­mo­ny out of fear for Lenny’s safe­ty. ” . . . . I safe­guard­ed his infor­ma­tion and his depo­si­tion for all of these years, fear­ful that the assas­s­in’s mas­ters would kill him if they learned about his coop­er­a­tion with me. . . .”

Before con­clud­ing the pro­gram, we revis­it the state­ment of one of the Spe­cial Forces offi­cers com­pris­ing the back-up fire team–a man Pep­per described under the pseu­do­nym “War­ren.” ” . . . .  . . . . War­ren said that on that occa­sion they also had a sec­ondary mis­sion, which was to do recon (recon­nais­sance of a home up in the West­ern Hills near the UCLA cam­pus.) The recon was to deter­mine the fea­si­bil­i­ty of a ‘wet insert ops deter­mined’ oper­a­tion. (‘Wet insert ops deter­mined’ means that the unit car­ries out a sur­rep­ti­tious entry at night into the tar­get­ed res­i­dence, kills every­one there, and leaves with­out a trace.)  He said that their recon deter­mined the fea­si­bil­i­ty of such an oper­a­tion. War­ren sub­se­quent­ly learned that the house was used by Sen­a­tor Robert F. Kennedy when he was in Los Ange­les in 1967–68. . . .”

We end the pro­gram with a caveat deliv­ered to for­mer Rep­re­sen­ta­tive Wal­ter Faun­troy [of Wash­ing­ton D.C.]–a founder of the Con­gres­sion­al Black Cau­cus. After inform­ing then Speak­er of the House of Rep­re­sen­ta­tives Carl Albert that he wished to head what was to become the House Select Com­mit­tee on Assas­si­na­tions: ” . . . . Albert said to him, ‘Wal­ter, you don’t want that job.’ To which Faun­troy replied, ‘But I do want it; why not?’ Albert whis­pered, ‘Wal­ter, they will kill you.’ . . .”

FTR #1132 Bio-Psy-Op Apocalypse Now, Part 8: Remdesivir Uber Alles

This broad­cast details the process of vet­ting the anti-Covid-19 drug remde­sivir, high­light­ing the insti­tu­tion­al short­cuts tak­en in test­ing the prod­uct, as well as the dubi­ous nature of the bil­lion­aires net­work­ing with offi­cials involved in the approval process.

Before ana­lyz­ing remde­sivir, how­ev­er, we update dis­cus­sion about the SARS CoV‑2 virus hav­ing been engi­neered, not­ing joint U.S.-Chinese projects in which bat-borne coro­n­avirus­es were genet­i­cal­ly engi­neered. The process­es used to mod­i­fy the virus­es would not show any overt evi­dence of human manip­u­la­tion.

Most impor­tant­ly, these projects received financ­ing from insti­tu­tions with doc­u­ment­ed links to U.S. intel­li­gence and mil­i­tary inter­ests.

Research into the his­to­ry of GOF (gain-of-func­tion) work on bat coro­n­avirus­es at the Wuhan Insti­tute of Virol­o­gy indi­cates mul­ti­ple areas of U.S. intel­li­gence pres­ence in that work. 

It was pub­licly dis­closed in a 2017 paper that the US and Chi­na col­lab­o­rat­ed on “gain-of-func­tion” research on bat coro­n­avirus­es to infect humans and that the work received fund­ing from the Unit­ed States Agency for Inter­na­tion­al Development–a fre­quent cut-out for the CIA.

In addi­tion, the work was also fund­ed in part by the Nation­al Insti­tutes of Health, which have col­lab­o­rat­ed with both CIA and the Pen­ta­gon in BSL‑4 (Bio-Safe­ty-Lev­el 4) projects. 

The Wuhan Insti­tute of Virol­o­gy has also part­nered with the USAMRIID since the mid-1980’s.

Impor­tant to note is the fact that it was pub­lic infor­ma­tion that some of this work was done in a biosafe­ty-lev­el 2 lab­o­ra­to­ry, giv­ing an observ­er intent on under­tak­ing a bio­log­i­cal war­fare covert oper­a­tion against Chi­na use­ful field intel­li­gence about the vul­ner­a­bil­i­ty of WIV for such an “op.”

1.–The inves­ti­ga­tion of infec­tiv­i­ty used unde­tectable meth­ods, negat­ing arti­cles claim­ing the virus could not have been genet­i­cal­ly engi­neered: ” Evi­dence has emerged that researchers at the Wuhan Insti­tute of Virol­o­gy (WIV) in Chi­na, work­ing in col­lab­o­ra­tion with sci­en­tists in the USA, have been genet­i­cal­ly engi­neer­ing bat virus­es for the past sev­er­al years to inves­ti­gate infec­tiv­i­ty – using unde­tectable meth­ods. . . . The evi­dence rebuts claims by jour­nal­ists and some sci­en­tists that the SARS-CoV­‑2 virus respon­si­ble for the cur­rent COVID-19 pan­dem­ic could not have been genet­i­cal­ly engi­neered because it lacks the ‘signs’ or ‘sig­na­tures’ that sup­pos­ed­ly would be left behind by genet­ic engi­neer­ing tech­niques. . . .”

2.–Dr. Richard Ebright not­ed that the research was joint­ly fund­ed by the U.S. and Chi­na, that Peter Daszak (about whom we have voiced reser­va­tions in the past) was one of the Amer­i­can col­lab­o­ra­tors. Fur­ther­more, the research was fund­ed in part by USAID, a com­mon U.S. intel­li­gence cut-out. ” . . . . Dr Richard Ebright, an infec­tious dis­ease expert at Rut­gers Uni­ver­si­ty (USA), has alert­ed the pub­lic to evi­dence that WIV and US-based researchers were genet­i­cal­ly engi­neer­ing bat virus­es to inves­ti­gate their abil­i­ty to infect humans, using com­mon­ly used meth­ods that leave no sign or sig­na­ture of human manip­u­la­tion. Ebright flagged up a sci­en­tif­ic paper pub­lished in 2017 by WIV sci­en­tists, includ­ing Shi Zhengli, the virol­o­gist lead­ing the research into bat coro­n­avirus­es, work­ing in col­lab­o­ra­tion with Peter Daszak of the US-based Eco­Health Alliance. Fund­ing was shared between Chi­nese and US insti­tu­tions, the lat­ter includ­ing the US Nation­al Insti­tutes of Health and USAID. The researchers report hav­ing con­duct­ed virus infec­tiv­i­ty exper­i­ments where genet­ic mate­r­i­al is com­bined from dif­fer­ent vari­eties of SARS-relat­ed coro­n­avirus­es to form nov­el ‘chimeric’ ver­sions. This formed part of their research into what muta­tions were need­ed to allow cer­tain bat coro­n­avirus­es to bind to the human ACE2 recep­tor – a key step in the human infec­tiv­i­ty of SARS-CoV­‑2. . . .”

3.–Furthermore, the researchers used a type of genet­ic engi­neer­ing that leaves no sig­na­ture of human manip­u­la­tion: ” . . . . The WIV sci­en­tists did this, Ebright points out, ‘using ‘seam­less lig­a­tion’ pro­ce­dures that leave no sig­na­tures of human manip­u­la­tion’. This is note­wor­thy because it is a type of genet­ic engi­neer­ing that Ander­sen and his team exclud­ed from their inves­ti­ga­tion into whether SARS-CoV­‑2 could have been engi­neered – and it was in use at the very lab that is the prime sus­pect for a lab escape. . . .”

4.–In addi­tion, Ebright high­lights the 2015 work done by Ralph Bar­ic in col­lab­o­ra­tion with WIV’s Shi Zhengli–a project we have dis­cussed at length in the past: ” . . . . A group of sci­en­tists from the Uni­ver­si­ty of North Car­oli­na in the USA, with the WIV’s Shi Zhengli as a col­lab­o­ra­tor, pub­lished a study in 2015 describ­ing sim­i­lar exper­i­ments involv­ing chimeric coro­n­avirus­es, which were also cre­at­ed using stan­dard unde­tectable genet­ic engi­neer­ing tech­niques. . . .”

5.–Ebright also cites work done in a bio-safe­ty lev­el 2 lab­o­ra­to­ry. : ” . . . . Ebright points out that the paper states, ‘All work with the infec­tious virus was per­formed under biosafe­ty lev­el 2 con­di­tions’. This lev­el is suit­able for work involv­ing agents of only ‘mod­er­ate poten­tial haz­ard to per­son­nel and the envi­ron­ment’. . . .But they are not at fault in fail­ing to use BSL‑4 for this work, as SARS coro­n­avirus­es are not aerosol-trans­mit­ted. The work does, how­ev­er, fall under biosafe­ty lev­el 3, which is for work involv­ing microbes that can cause seri­ous and poten­tial­ly lethal dis­ease via inhala­tion. . . .”

6.–Dr. Jonathan Lath­am under­scored the reser­va­tions expressed by many con­cern­ing “gain-of-func­tion” exper­i­ments on these kinds of coro­n­avirus­es: ” . . . . The bio­sci­en­tist Dr Jonathan Lath­am crit­i­cised the kind of research on bat coro­n­avirus­es that has been tak­ing place in Wuhan and the USA as ‘pro­vid­ing an evo­lu­tion­ary oppor­tu­ni­ty’ for such virus­es ‘to jump into humans’. Lath­am, who has a doc­tor­ate in virol­o­gy, argues that this kind of work is sim­ply ‘pro­vid­ing oppor­tu­ni­ties for con­t­a­m­i­na­tion events and leak­ages from labs, which hap­pen on a rou­tine basis’. . . .”

U.S. Army Med­ical Research Insti­tute of Infec­tious Disease–located at Ft. Det­rick and closed by the CDC for safe­ty vio­la­tions in August, 2019.

Note, again, that the whole world was informed back in 2017 that  dan­ger­ous research involv­ing the cre­ation of bat coro­n­avirus­es to infect humans was being car­ried out in Chi­na.  Note again, that the research was fund­ed in part by the US, includ­ing USAID–a fre­quent U.S. intel­li­gence cut-out; the NIH–which has active­ly col­lab­o­rat­ed with both CIA and Pen­ta­gon. The WIV has also part­nered with the USAMRIID.

Flash for­ward a cou­ple of years and we have a night­mare virus that ini­tial­ly appeared to pop up near­by the WIV, with the Trump admin­is­tra­tion aggres­sive­ly push­ing the idea that it escaped from that lab.

In that con­text, we note the fol­low­ing:

1.–In 2017, Chi­na got approval for its first BSL‑4 lab in Wuhan, the first of sev­er­al planned BSL‑4 labs. “A lab­o­ra­to­ry in Wuhan is on the cusp of being cleared to work with the world’s most dan­ger­ous pathogens. The move is part of a plan to build between five and sev­en biosafe­ty level‑4 (BSL‑4) labs across the Chi­nese main­land by 2025, and has gen­er­at­ed much excite­ment, as well as some con­cerns. . . . Some sci­en­tists out­side Chi­na wor­ry about pathogens escap­ing, and the addi­tion of a bio­log­i­cal dimen­sion to geopo­lit­i­cal ten­sions between Chi­na and oth­er nations. . . .”

2.–As will be seen below, the pro­lif­er­a­tion of BSL‑4 labs has sparked wor­ries about “dual use” tech­nol­o­gy: ” . . . . The expan­sion of BSL-4-lab net­works in the Unit­ed States and Europe over the past 15 years — with more than a dozen now in oper­a­tion or under con­struc­tion in each region — also met with resis­tance, includ­ing ques­tions about the need for so many facil­i­ties. . . .”

3.–The above-men­tioned Richard Ebright notes that the pro­lif­er­a­tion of BSL‑4 labs will spur sus­pi­cion of “dual use” tech­nol­o­gy, in which osten­si­ble med­ical research masks bio­log­i­cal war­fare research: ” . . . . But Ebright is not con­vinced of the need for more than one BSL‑4 lab in main­land Chi­na. He sus­pects that the expan­sion there is a reac­tion to the net­works in the Unit­ed States and Europe, which he says are also unwar­rant­ed. He adds that gov­ern­ments will assume that such excess capac­i­ty is for the poten­tial devel­op­ment of bioweapons. ‘These facil­i­ties are inher­ent­ly dual use,’ he says. . . .”

In the con­text of the above arti­cles, note that the Nation­al Insti­tutes of Health have also part­nered with CIA and the Pen­ta­gon, as under­scored by an arti­cle about a BSL‑4 lab at Boston Uni­ver­si­ty. Note that the U.S. and Europe have twelve BSL4 labs apiece, Tai­wan has two, while Chi­na has one:

1.–As the arti­cle notes, as of 2007, the U.S. had “more than a dozen” BSL4 labs–China com­mis­sioned its first as of 2017. a ten­fold increase in fund­ing for BSL4 labs occurred because of the anthrax attacks of 2001. Those attacks might be seen as some­thing of a provo­ca­tion, spurring a dra­mat­ic increase in “dual use” biowar­fare research, under the cov­er of “legit­i­mate” medical/scientific research. In FTR #1128, we hypoth­e­sized about the milieu of Stephen Hat­fill and apartheid-linked inter­ests as pos­si­ble authors of a vec­tor­ing of New York City with Sars COV2: ” . . . . Before the anthrax mail­ings of 2001, the Unit­ed States had just two BSL4 labs—both with­in the razor-wire con­fines of gov­ern­ment-owned cam­pus­es. Now, thanks to a ten­fold increase in funding—from $200 mil­lion in 2001 to $2 bil­lion in 2006—more than a dozen such facil­i­ties can be found at uni­ver­si­ties and pri­vate com­pa­nies across the coun­try. . . .”

2.–The Boston Uni­ver­si­ty lab exem­pli­fies the Pen­ta­gon and CIA pres­ence in BSL‑4 facil­i­ty “dual use”: ” . . . . But some sci­en­tists say that argu­ment obscures the true pur­pose of the cur­rent biode­fense boom: to study poten­tial bio­log­i­cal weapons. ‘The uni­ver­si­ty por­trays it as an emerg­ing infec­tious dis­ease lab,’ says David Ozonoff, a Boston Uni­ver­si­ty epi­demi­ol­o­gist whose office is right across the street from the new BSL4 facil­i­ty. ‘But they are talk­ing about study­ing things like small pox and inhala­tion anthrax, which pose no pub­lic health threat oth­er than as bioweapons.’ . . . The orig­i­nal NIH man­date for the lab indi­cat­ed that many groups—including the CIA and Depart­ment of Defense—would be allowed to use the lab for their own research, the nature of which BU might have lit­tle con­trol over. . . .”

Note, also that:

1.–The WIV has part­nered with the U.S. Army’s Med­ical Research Insti­tute of Infec­tious Dis­eases, locat­ed at Ft. Det­rick.

2.–In ear­ly August of 2019, short­ly before the record­ed start of the out­break in Wuhan, Chi­na, the U.S. Army Med­ical Research Insti­tute of Infec­tious Dis­eases at that facil­i­ty was closed down by the CDC due to mul­ti­ple safe­ty violations.“All research at a Fort Det­rick lab­o­ra­to­ry that han­dles high-lev­el dis­ease-caus­ing mate­r­i­al, such as Ebo­la, is on hold indef­i­nite­ly after the Cen­ters for Dis­ease Con­trol and Pre­ven­tion found the orga­ni­za­tion failed to meet biosafe­ty stan­dards. . . . The CDC sent a cease and desist order in July. After USAMRIID received the order from the CDC, its reg­is­tra­tion with the Fed­er­al Select Agent Pro­gram, which over­sees dis­ease-caus­ing mate­r­i­al use and pos­ses­sion, was sus­pend­ed. That sus­pen­sion effec­tive­ly halt­ed all bio­log­i­cal select agents and tox­in research at USAMRIID . . . .”

Fol­low­ing the update on the WIV and BSL‑4 lab­o­ra­to­ries, we piv­ot to analy­sis of the ele­va­tion of remde­sivir as the “go-to” treat­ment du jour for Covid-19. Of para­mount impor­tance is the remark­able time­line: The DSMB (data safe­ty and mon­i­tor­ing board) ” . . . . the DSMB for the remde­sivir study did not ever meet for an inter­im effi­ca­cy analy­sis, Lane said. All patients had been enrolled by April 20. The data for a DSMB meet­ing was cut off on April 22. The DSMB met and, on April 27, it made a rec­om­men­da­tion to the NIAID. . . . That deci­sion, Lane said, led the NIAID to con­clude that patients who had been giv­en place­bo should be offered remde­sivir, some­thing that start­ed hap­pen­ing after April 28. . . .” 

As will be seen, it was on 4/29 that Joe Gro­gan resigned. (See below.)

When pos­i­tive news on a NIAID study on the drug remde­sivir were released–on 4/29–it drove broad gains in the stock mar­ket. In FTR #1131, we not­ed that dis­clo­sures con­cern­ing pos­i­tive news about Mod­er­na’s exper­i­men­tal Covid-19 vac­cine also proved to be a sim­i­lar dri­ver of the stock mar­ket, as well as of Mod­er­na’s stock.

Dis­cus­sion of the hard details of sev­er­al remde­sivir tri­als begins with dis­cus­sion of an NIAID tri­al that helped move the mar­kets, as seen above. The tri­al was a mod­est suc­cess, indi­cat­ing that recov­ery for recent­ly infect­ed patients was about 31% faster than for place­bo. There was no sig­nif­i­cant sta­tis­ti­cal dif­fer­ence in mortality–the most impor­tant mea­sure of effec­tive­ness accord­ing to many experts.

” . . . . Dur­ing an appear­ance along­side Pres­i­dent Trump in the Oval Office, Antho­ny Fau­ci, the direc­tor of NIAID, part of the Nation­al Insti­tutes of Health, said the data are a ‘very impor­tant proof of con­cept’ and that there was rea­son for opti­mism. He cau­tioned the data were not a ‘knock­out.’ At the same time, the study achieved its pri­ma­ry goal, which was to improve the time to recov­ery, which was reduced by four days for patients on remde­sivir. The pre­lim­i­nary data showed that the time to recov­ery was 11 days on remde­sivir com­pared to 15 days for place­bo, a 31% decrease. The mor­tal­i­ty rate for the remde­sivir group was 8%, com­pared to 11.6% for the place­bo group; that mor­tal­i­ty dif­fer­ence was not sta­tis­ti­cal­ly sig­nif­i­cant. . . .”

Next we present a Stat News arti­cle on the inter­nal delib­er­a­tions behind the deci­sions to mod­i­fy the NIAID study. Of par­tic­u­lar sig­nif­i­cance is the DSMB delib­er­a­tion. Note the time­line of the DSMB delib­er­a­tion, com­bined with the announce­ment on 4/29 that drove the mar­kets high­er.

1.–The deci­sion was made to cut it short before the ques­tion of remdesivir’s impact on mor­tal­i­ty could be answered: ” . . . .The Nation­al Insti­tute of Aller­gy and Infec­tious Dis­eases has described to STAT in new detail how it made its fate­ful deci­sion: to start giv­ing remde­sivir to patients who had been assigned to receive a place­bo in the study, essen­tial­ly lim­it­ing researchers’ abil­i­ty to col­lect more data about whether the drug saves lives — some­thing the study, called ACTT‑1, sug­gests but does not prove. In the tri­al, 8% of the par­tic­i­pants giv­en remde­sivir died, com­pared with 11.6% of the place­bo group, a dif­fer­ence that was not sta­tis­ti­cal­ly sig­nif­i­cant. A top NIAID offi­cial said he had no regrets about the deci­sion. ‘There cer­tain­ly was una­nim­i­ty with­in the insti­tute that this was the right thing to do,’ said H. Clif­ford Lane, NIAID’s clin­i­cal direc­tor. . . .”

2.–In addi­tion, patients sched­uled to receive place­bo received remde­sivir, instead. ” . . . . Steven Nis­sen, a vet­er­an tri­al­ist and car­di­ol­o­gist at the Cleve­land Clin­ic, dis­agreed that giv­ing place­bo patients remde­sivir was the right call. ‘I believe it is in society’s best inter­est to deter­mine whether remde­sivir can reduce mor­tal­i­ty, and with the release of this infor­ma­tion doing a place­bo-con­trolled tri­al to deter­mine if there is a mor­tal­i­ty ben­e­fit will be very dif­fi­cult,’ he said. ‘The ques­tion is: Was there a route, or is there a route, to deter­mine if the drug can pre­vent death?’ The deci­sion is ‘a lost oppor­tu­ni­ty,’ he said. . . .”

3.–Steven Nis­sen was not alone in his crit­i­cism of the NIAID’s deci­sion. ” . . . .Peter Bach, the direc­tor of the Cen­ter for Health Pol­i­cy and Out­comes at Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter, agreed with Nis­sen. ‘The core under­stand­ing of clin­i­cal research par­tic­i­pa­tion and clin­i­cal research con­duct is we run the tri­al rig­or­ous­ly to pro­vide the most accu­rate infor­ma­tion about the right treat­ment,’ he said. And that answer, he argued, should ide­al­ly have deter­mined whether remde­sivir saves lives. The rea­son we have shut our whole soci­ety down, Bach said, is not to pre­vent Covid-19 patients from spend­ing a few more days in the hos­pi­tal. It is to pre­vent patients from dying. ‘Mor­tal­i­ty is the right end­point,’ he said. . . .”

4.–Not only was the admin­is­tra­tion of remde­sivir instead of place­bo pri­or­i­tized, but the NIAID study itself was atten­u­at­ed! ” . . . . But the change in the study’s main goal also changed the way the study would be ana­lyzed. Now, the NIAID decid­ed, the analy­sis would be cal­cu­lat­ed when 400 patients out of the 1,063 patients the study enrolled had recov­ered. If remde­sivir turned out to be much more effec­tive than expect­ed, ‘inter­im’ analy­ses would be con­duct­ed at a third and two-thirds that number.The job of review­ing these analy­ses would fall to a com­mit­tee of out­side experts on what is known as an inde­pen­dent data and safe­ty mon­i­tor­ing board, or DSMB. . . .”

5.–The per­for­mance of the DSMB for the remde­sivir study is note­wor­thy: ” . . . . But the DSMB for the remde­sivir study did not ever meet for an inter­im effi­ca­cy analy­sis, Lane said. All patients had been enrolled by April 20. The data for a DSMB meet­ing was cut off on April 22. The DSMB met and, on April 27, it made a rec­om­men­da­tion to the NIAID. . . .”

6.–The DSMB meet­ing on 4/27 deter­mined the switch from place­bo to remde­sivir. Of para­mount impor­tance is the fact that this was JUST BEFORE the 4/29 announce­ment that drove the mar­kets high­er and the same day on which key Trump aide–and for­mer Gilead Sci­ences lob­by­ist Joe Gro­gan resigned! ” . . . . . That deci­sion, Lane said, led the NIAID to con­clude that patients who had been giv­en place­bo should be offered remde­sivir, some­thing that start­ed hap­pen­ing after April 28. . . .”

7.–Dr. Ethan Weiss gave an accu­rate eval­u­a­tion of the NIAID study: ” . . . . ‘We’ve squan­dered an incred­i­ble oppor­tu­ni­ty to do good sci­ence,’ [Dr. Ethan] Weiss said. ‘If we could ever go back and do some­thing all over, it would be the infra­struc­ture to actu­al­ly learn some­thing. Because we’re not learn­ing enough.’ . . . .”

Next, we ana­lyze a STAT News excerpt that goes into more of the con­cerns about the Gilead study design.

The Gilead study was designed with­out any con­trol group, so the ques­tion of how much remde­sivir actu­al­ly helps sick patients (or doesn’t help) can’t be defin­i­tive­ly answered by that study.

The arti­cle also gives Gilead’s expla­na­tion for why they left out a con­trol group: due to the lim­it­ed sup­plies of the drug the com­pa­ny decid­ed to pri­or­i­tize on pro­duc­ing more of the drug itself rather than a place­bo con­trol. It’s an expla­na­tion that only makes sense if pro­duc­ing place­bo dos­es was some­how a sig­nif­i­cant tech­ni­cal chal­lenge, which seems dubi­ous.

Due to a lack of a con­trol group, the study instead focus­es on answer­ing the ques­tion of whether or not the recov­ery times for patients dif­fers between groups receiv­ing a 10-day course of the drug vs a 5‑day course. The patients were severe­ly ill but not on ven­ti­la­tors when enrolled in the study (so the patients that need the drug most weren’t test­ed). The pre­lim­i­nary results released Wednes­day sug­gest there is no dif­fer­ence between the recov­ery times for the two groups.

1.–The Gilead study lacked a con­trol group: ” . . . .  But out­side experts in clin­i­cal tri­al design wor­ry that the results, instead of lead­ing to a clear pic­ture of whether the med­i­cine is effec­tive, will instead mud­dy the waters fur­ther. The main con­cern, they say, stems from the fact that the Gilead tri­al expect­ed to read out this week, which was con­duct­ed among patients with severe dis­ease, lacks a con­trol group — that is, patients who are ran­dom­ly assigned to receive the best treat­ment avail­able, but not remde­sivir. As designed, the only ran­dom­iza­tion is the dura­tion of treat­ment: either five days or 10 days of drug. With­out a true con­trol group of patients, many experts say, it will be dif­fi­cult to deter­mine whether remde­sivir is effec­tive. . . .”

2.–The above-men­tioned Steven Nis­sen summed up the use­ful­ness of the Gilead tri­al. ” . . . . ‘The over­all study itself has lit­tle or no sci­en­tif­ic val­ue since all patients are receiv­ing the drug,’ said Steven Nis­sen, the chief aca­d­e­m­ic offi­cer at the Cleve­land Clin­ic and lead inves­ti­ga­tor of many tri­als for heart drugs that have been approved by the Food and Drug Admin­is­tra­tion. ‘The study, as designed, is essen­tial­ly use­less and can­not be used by the FDA for con­sid­er­a­tion of remde­sivir for approval to treat coro­n­avirus,’ Nis­sen said. . . .”

3.–Gilead’s spokesper­son alleged that the com­pa­ny had a lim­it­ed sup­ply of place­bo and remde­sivir. ” . . . . ‘In the ear­ly stages of the pan­dem­ic, we not only had a lim­it­ed sup­ply of remde­sivir but also a lim­it­ed sup­ply of the matched place­bo required for place­bo-con­trolled stud­ies,’ said Amy Flood, a Gilead spokesper­son. ‘We chose to pri­or­i­tize man­u­fac­tur­ing active drug over place­bo, and we pro­vid­ed our sup­ply of place­bo to Chi­na and NIAID for their stud­ies of remde­sivir.’ . . .”

5.–A num­ber of crit­ics shared Steven Nis­sen’s opin­ion about the sci­en­tif­ic val­ue of the study. ” . . . . Crit­ics point to Gilead’s deci­sion to com­pare two groups giv­en remde­sivir for either five days or 10 days. The prob­lem with this strat­e­gy, they say, is that an inef­fec­tive drug that did noth­ing and a very effec­tive drug that con­sis­tent­ly helped patients over­come the virus would look the same in such a study. Only if the 10-day course were more effec­tive, or if it was worse because of side effects, would the study have any clear result. . . .”

6.–Nissen was more opti­mistic about a sec­ond forth­com­ing Gilead tri­al. Sloan Ket­ter­ing’s Peter Bach did not share that opti­mism. ” . . . .Yet anoth­er tri­al in less sick patients, also run by Gilead, does have a con­trol group and may give a clear­er answer. Nis­sen sees ‘a rea­son­able study design.’ But Bach was more crit­i­cal, say­ing that even though that study has a con­trol group, the lack of a place­bo means the study might not be trust­wor­thy. That’s because its main goal, time to improve­ment of symp­toms, could be affect­ed by the per­cep­tions of clin­i­cians and the patients them­selves. Bach said the hos­pi­tals con­duct­ing the study ‘are eas­i­ly capa­ble of wrap­ping syringes in brown paper and blind­ing the whole thing. I don’t under­stand why you would run a tri­al like this.’ . . . .”

Although it was cut short due to the wan­ing of the pan­dem­ic in Chi­na, a WHO-leaked study was not encour­ag­ing with regard to remde­sivir’s effi­ca­cy as a treat­ment for Covid-19.

1.–The Chi­nese study was a ram­dom­ized con­trolled tri­al: ” . . . . Encour­ag­ing data from patients in that study at the Uni­ver­si­ty of Chica­go were described by researchers at a vir­tu­al town hall and obtained by STAT last week. How­ev­er, unlike those data, these new results are from a ran­dom­ized con­trolled tri­al, the med­ical gold stan­dard. . . .”

2.–The Chi­nese study found that remde­sivir was of no val­ue in pre­vent­ing Covid-19 deaths. As not­ed above, the effect of the drug on mor­tal­i­ty was the main con­sid­er­a­tion. Our soci­ety has not been shut down to afford peo­ple short­er stays in the hos­pi­tal, but to pre­vent death. ” . . . . Accord­ing to the sum­ma­ry of the Chi­na study, remde­sivir was ‘not asso­ci­at­ed with a dif­fer­ence in time to clin­i­cal improve­ment’ com­pared to a stan­dard of care con­trol. After one month, it appeared 13.9% of the remde­sivir patients had died com­pared to 12.8% of patients in the con­trol arm. The dif­fer­ence was not sta­tis­ti­cal­ly sig­nif­i­cant. . . .”

3.–The Chi­nese study pro­duced a grim assess­ment of remde­sivir: ” . . . . ‘In this study of hos­pi­tal­ized adult patients with severe COVID-19 that was ter­mi­nat­ed pre­ma­ture­ly, remde­sivir was not asso­ci­at­ed with clin­i­cal or viro­log­i­cal ben­e­fits,’ the sum­ma­ry states. The study was ter­mi­nat­ed pre­ma­ture­ly because it was dif­fi­cult to enroll patients in Chi­na, where the num­ber of Covid-19 cas­es was decreas­ing. An out­side researcher said that the results mean that any ben­e­fit from remde­sivir is like­ly to be small. ‘If there is no ben­e­fit to remde­sivir in a study this size, this sug­gests that the over­all ben­e­fit of remde­sivir in this pop­u­la­tion with advanced infec­tion is like­ly to be small in the larg­er Gilead tri­al,’ said Andrew Hill, senior vis­it­ing research fel­low at Liv­er­pool Uni­ver­si­ty. . . .”

After dis­cussing a num­ber of prob­lems that Gilead Sci­ences may encounter in the pro­duc­tion of sig­nif­i­cant quan­ti­ties of remde­sivir to be effec­tive, the broad­cast con­cludes with dis­cus­sion of the inap­pro­pri­ate­ly-named “Sci­en­tists to Stop Covid-19.”

The remark­able han­dling of the NIAID study, the tim­ing of the announce­ment of the alto­geth­er lim­it­ed suc­cess of the atten­u­at­ed tri­al, and the rise in equi­ties as a result of the announce­ment may be best under­stood in the con­text of the role played in Trump pan­dem­ic deci­sion-mak­ing by an elite group of bil­lion­aires and scientists–including Peter Thiel and con­vict­ed felon Michael Milken (the “junk bond king”).

1.–” . . . . Call­ing them­selves ‘Sci­en­tists to Stop COVID-19,’ the col­lec­tion of top researchers, bil­lion­aires and indus­try cap­tains will act as an ‘ad hoc review board’ for the tor­rent of coro­n­avirus research, ‘weed­ing out’ flawed data before it reach­es pol­i­cy­mak­ers, the Wall Street Jour­nal report­ed on Mon­day. They are also act­ing as a go-between for phar­ma­ceu­ti­cal com­pa­nies seek­ing to build a com­mu­ni­ca­tion chan­nel with Trump admin­is­tra­tion offi­cials. The group . . . . has advised Nick Ayers, an aide to Vice Pres­i­dent Mike Pence, as well as oth­er agency heads, in the past month. Pence is head­ing up the White House coro­n­avirus task force. . . .”

2.–” . . . The brainy bunch is led by Thomas Cahill, a 33-year-old doc­tor who became a ven­ture cap­i­tal­ist . . . . Cahill’s clout comes from build­ing con­nec­tions through his invest­ment firm, New­path Part­ners, with Sil­i­con Valley’s Peter Thiel, the founder of Pay­Pal, and bil­lion­aire busi­ness­men Jim Palot­ta and Michael Milken. . . .”

Note that Thiel played a dom­i­nant role in bankrolling New­path Part­ners, and the oth­er finan­cial angel who ele­vat­ed Cahill–Brian Sheth–introduced him to Tom­my Hicks, Jr., the co-chair­man of the RNC. In FTR #‘s 1111 and 1112, we looked at Hicks’ net­work­ing with Steve Ban­non asso­ciate J. Kyle Bass, as well as his role in the inter-agency net­works dri­ving the anti-Chi­na effort.

1.–” . . . . At the helm of the effort: The 33-year-old and very-much-under-the-radar ven­ture cap­i­tal­ist Tom Cahill, who leads life sci­ences-focused New­path Part­ners. Cahill com­plet­ed his M.D. and PhD at Duke Uni­ver­si­ty a mere two years ago before land­ing at blue-chip invest­ment firm Rap­tor Group through a friend. He went on to found New­path with some $125 mil­lion after impress­ing well-con­nect­ed names like ven­ture cap­i­tal­ist Peter Thiel and Vista Equi­ty Part­ners co-founder Bri­an Sheth. . . . It was through Sheth, for exam­ple, that Sci­en­tists to Stop Covid-19 con­nect­ed with the co-chair­man of the Repub­li­can Nation­al Com­mit­tee, Thomas Hicks Jr. . . .”

The fed­er­al gov­ern­men­t’s extreme focus on remde­sivir has been shaped, in large mea­sure, by the influ­ence of “Sci­en­tists to Stop COVID-19”:

1.–“Scientists to Stop Covid-19” is shep­herd­ing remde­sivir: ” . . . . Sci­en­tists to Stop COVID-19 rec­om­mends that in this phase, the U.S. Food and Drug Admin­is­tra­tion (FDA) should work to coor­di­nate with Gilead phar­ma­ceu­ti­cals to focus on expe­dit­ing the results of clin­i­cal tri­als of remde­sivir, a drug iden­ti­fied as a poten­tial treat­ment for COVID-19. The group also rec­om­mends admin­is­ter­ing dos­es of the drug to patients in an ear­ly stage of infec­tion, and notes remde­sivir will essen­tial­ly be a place­hold­er until a more effec­tive treat­ment is pro­duced.

2.–The group is doing so by atten­u­at­ing the reg­u­la­to­ry process for coro­n­avirus drugs: “Gov­ern­ment enti­ties and agen­cies appear to adhere to the rec­om­men­da­tions out­lined by the group, with the Jour­nal report­ing that the FDA and the Depart­ment of Vet­er­ans Affairs (VA) have imple­ment­ed some of the sug­ges­tions, name­ly relax­ing drug man­u­fac­tur­er reg­u­la­tions and require­ments for poten­tial coro­n­avirus treat­ment drugs. . . .”

We con­clude with a piece about the announce­ment of Grogan’s depar­ture.

” . . . . Gro­gan has served as the direc­tor of the White House Domes­tic Pol­i­cy Coun­cil since Feb­ru­ary 2019, over­see­ing a broad array of pol­i­cy issues includ­ing health care and reg­u­la­tion. . . . Gro­gan was one of the orig­i­nal mem­bers of the White House coro­n­avirus task force launched in late Jan­u­ary. . . . Gro­gan worked as a lob­by­ist for drug com­pa­ny Gilead Sci­ences before join­ing the Trump admin­is­tra­tion. . . .”

The depar­ture was announced in the Wall Street Jour­nal on the morn­ing of Wednes­day, April 29, the same day we got our first pub­lic reports of the NIAID clin­i­cal tri­al of remde­sivir that was pos­i­tive enough to show it short­ened the time to recov­ery and the same day the FDA grant­ed remde­sivir emer­gency use sta­tus. 

Note, again, the tim­ing of the DSM­B’s actions, as well as the imflu­ence of “Sci­en­tists to Stop Covid-19.”

Complications With The “Chinese-Lab-Did-It” Theory

A new arti­cle from “GMWatch” details work at the Wuhan Insti­tute of Virol­o­gy involv­ing genet­ic manip­u­la­tion of bat-borne coro­n­avirus­es sim­i­lar to the SARS CoV‑2. These manip­u­la­tions involved genet­ic engi­neer­ing tech­niques that would not be detectable as such. Most impor­tant­ly, these experiments–reported in papers pub­lished in 2017–were joint U.S.-Chinese under­tak­ings, with insti­tu­tion­al par­tic­i­pa­tion and financ­ing by orga­ni­za­tions con­nect­ed to Amer­i­can intel­li­gence and the Pen­ta­gon. Specif­i­cal­ly, the exper­i­ments were financed, in part, by USAID–a fre­quent “cut-out” for CIA and oth­er agen­cies’ “ops.” In addi­tion, the Nation­al Insti­tutes of Health were finan­cial­ly and oper­a­tional­ly involved in the experiments–NIH has net­worked with both the CIA and Pen­ta­gon on BSL‑4 (Bio-Safe­ty-Lev­el 4) projects. Worth not­ing is that the 2017 paper dis­closed that some of the work was done at a Bio-Safe­ty-Lev­el 2 lab, a rel­a­tive­ly low-secu­ri­ty insti­tu­tion. This offered a would-be male­fac­tor field intel­li­gence that would be use­ful for stag­ing a “virus-escaped-from-Chi­nese-Lab” gam­bit. A “Nature” arti­cle notes that Chi­na was about to open its first BSL‑4 lab with help from Europe. The proflif­er­a­tion of BSL‑4 labs is wor­ri­some to some observers: ” . . . . The expan­sion of BSL-4-lab net­works in the Unit­ed States and Europe over the past 15 years — with more than a dozen now in oper­a­tion or under con­struc­tion in each region — also met with resis­tance, includ­ing ques­tions about the need for so many facil­i­ties. . . . Some sci­en­tists out­side Chi­na wor­ry about pathogens escap­ing, and the addi­tion of a bio­log­i­cal dimen­sion to geopo­lit­i­cal ten­sions between Chi­na and oth­er nations.” Fur­ther­more : ” . . . . [Pro­fes­sor Richard] Ebright is not con­vinced of the need for more than one BSL‑4 lab in main­land Chi­na. He sus­pects that the expan­sion there is a reac­tion to the net­works in the Unit­ed States and Europe, which he says are also unwar­rant­ed. He adds that gov­ern­ments will assume that such excess capac­i­ty is for the poten­tial devel­op­ment of bioweapons. ‘These facil­i­ties are inher­ent­ly dual use,’ he says. . . .” In 2007, “Newsweek” fea­tured a sto­ry illus­trat­ing the use of uni­ver­si­ty BSL‑4 labs by CIA and the Pen­ta­gon, as a con­di­tion of an NIH con­tract with Boston Uni­ver­si­ty: ” . . . .The orig­i­nal NIH man­date for the lab indi­cat­ed that many groups—including the CIA and Depart­ment of Defense—would be allowed to use the lab for their own research, the nature of which BU might have lit­tle con­trol over. . . .” The Unit­ed States Army Med­ical Research Insti­tute of Infec­tious Dis­eases has net­worked with the WIV since the mid-1980s. As we have not­ed in a num­ber of pro­grams and posts, the USAMRIID was closed down in August of 2019 for safe­ty vio­la­tions.

Pottinger Agonistes: Covid-19 Disinformation Meets Weaponized Feminism

“A lib­er­al’s idea of courage is eat­ing at a restau­rant that has­n’t been reviewed yet.”–Mort Sahl. In FTR #‘s 998, 999 and 1000, we set forth what Mr. Emory calls “weaponized fem­i­nism.” Refash­ion­ing the doc­trine of advanc­ing the cause of women into a legal and polit­i­cal weapon for destroy­ing tar­get­ed men, dom­i­nant man­i­fes­ta­tions of the #MeToo move­ment have served the cause of the far right. In Mis­cel­la­neous Archive Show M4, we set forth Glo­ria Steinem’s work for the CIA and her nine years’ rela­tion­ship with J. Stan­ley Pot­tinger. In addi­tion to Steinem’s lover, Pot­tinger was: Assis­tant Attor­ney Gen­er­al for Civ­il Rights under Nixon and Ford; report­ed by Don­ald Freed and Fred Lan­dis (in “Death in Wash­ing­ton”) to have foiled inves­ti­ga­tions into the assas­si­na­tions of Mar­tin Luther King and Orlan­do Lete­lier; the attor­ney for the Hashe­mi broth­ers in the Octo­ber Sur­prise inves­ti­ga­tion and a close per­son­al friend of George H.W. Bush (for whom CIA head­quar­ters was named). Despite the fact that Steinem tout­ed her CIA back­ground as good jour­nal­is­tic cre­den­tials in both “The New York Times” and “The Wash­ing­ton Post” (both with long-stand­ing CIA links them­selves), Pot­tinger has defend­ed her against charges that she worked for the CIA!! J. Stan­ley Pot­tinger’s son Matthew is Trump’s Deputy Nation­al Secu­ri­ty Advi­sor and a point-man for the “Chi­na-did-it” Covid-19 meme. One won­ders if Matthew may have fol­lowed J. Stan­ley into the CIA, if in fact Dad­dio is Agency, as Mr. Emory sus­pects. We find it more than coin­ci­den­tal that Tara Read­e’s shape-shift­ing accu­sa­tions against Joe Biden have sur­faced decades after the alleged incident–coinciding with Biden’s chal­leng­ing of Trump and with Pot­tinger, Jr. help­ing to direct the admin­is­tra­tion’s traf­fic. Bernie Sanders sup­port­er Tara Read­e’s charge brings to mind George H.W. Bush cam­paign man­ag­er Lee Atwa­ter’s gam­bit of using Don­na Rice to destroy the Pres­i­den­tial can­di­da­cy of for­mer Sen­a­tor Gary Hart.

FTR #1109 Deutsche Bank, “Suicides,” The Supreme Court and Team Trump (Send in The Clowns, Part 2)

While the pub­lic’s atten­tion is focused on the impeach­ment pro­ceed­ings, high­ly sus­pi­cious infor­ma­tion has sur­faced involv­ing the finances of “Team Trump,” Deutsche Bank, osten­si­ble “sui­cides,” and appar­ent destruc­tion of finan­cial records.

With the fail­ure of a Trump fil­ing in appeals court, this con­cate­na­tion appears to be head­ed to the Supreme Court, where both Neil Gor­such and Brett Kavanaugh clerked for for­mer Jus­tice Antho­ny Kennedy. (Kavanaugh took Kennedy’s seat.) 

Dur­ing the con­fir­ma­tion hear­ings of both judges, none of the occu­pants of the Demo­c­ra­t­ic Sen­a­to­r­i­al Clown Car brought up the fact that Jus­tice Kennedy’s son Justin was in charge of Deutsche Bank’s real estate lend­ing depart­ment when the insti­tu­tion was Trump’s only lender. Justin Kennedy also had strong pro­fes­sion­al trans­ac­tions with Jared Kush­n­er’s real estate oper­a­tions, as well.

Thomas Bowers–a key Deutsche Bank offi­cial involved with Don­ald Trump’s deal­ings with the bank–allegedly com­mit­ted sui­cide in late Novem­ber of 2019, as “The Don­ald” attempt­ed to keep his finan­cial records from Con­gres­sion­al inves­ti­ga­tors. ” Thomas Bow­ers, iden­ti­fied as a for­mer Deutsche Bank exec­u­tive who signed off on con­tro­ver­sial loans to Pres­i­dent Don­ald Trump, died last week after appar­ent­ly tak­ing his own life at 55.. . . . ‘One source who has direct knowl­edge of the FBI’s inves­ti­ga­tion into Deutsche Bank said that fed­er­al inves­ti­ga­tors have asked about Bow­ers and doc­u­ments he might have. Anoth­er source who has knowl­edge of Deutsche Bank’s inter­nal struc­ture said that Bow­ers would have been the gate­keep­er for finan­cial doc­u­ments for the bank’s wealth­i­est cus­tomers.’ . . . .”

In addi­tion to Mr. Bow­ers, a Deutsche Bank exec­u­tive named William Broeksmit alleged­ly com­mit­ted sui­cide in 2014. His son, Val, has giv­en the FBI doc­u­ments involv­ing the bank’s deal­ings with Team Trump. “Fed­er­al author­i­ties are inves­ti­gat­ing whether Deutsche Bank com­plied with laws meant to stop mon­ey laun­der­ing and oth­er crimes, the lat­est gov­ern­ment exam­i­na­tion of poten­tial mis­con­duct at one of the world’s largest and most trou­bled banks . . . . The inves­ti­ga­tion includes a review of Deutsche Bank’s han­dling of so-called sus­pi­cious activ­i­ty reports that its employ­ees pre­pared about pos­si­bly prob­lem­at­ic trans­ac­tions, includ­ing some linked to Pres­i­dent Trump’s son-in-law and senior advis­er, Jared Kush­n­er . . . . The same fed­er­al agent who con­tact­ed Ms. McFadden’s lawyer also par­tic­i­pat­ed in inter­views of the son of a deceased Deutsche Bank exec­u­tive, William S. Broeksmit. . . . . . . . F.B.I. agents met this year with Val Broeksmit, whose father was a senior Deutsche Bank exec­u­tive who com­mit­ted sui­cide in Jan­u­ary 2014. Mr. Broeksmit said he had pro­vid­ed the agents with inter­nal bank doc­u­ments and oth­er mate­ri­als that he had retrieved from his father’s per­son­al email accounts. . . .”

Irreg­u­lar­i­ties sug­gest­ing mon­ey laun­der­ing also involved Deutsche Bank deal­ings with Jared Kush­n­er, Trump’s son-in-law. The bank ignored its employ­ees’ requests to rile reports with the gov­ern­ment. ” . . . . Anti-mon­ey-laun­der­ing spe­cial­ists at Deutsche Bank rec­om­mend­ed in 2016 and 2017 that mul­ti­ple trans­ac­tions involv­ing legal enti­ties con­trolled by Don­ald J. Trump and his son-in-law, Jared Kush­n­er, be report­ed to a fed­er­al finan­cial-crimes watch­dog. . . . .But exec­u­tives at Deutsche Bank, which has lent bil­lions of dol­lars to the Trump and Kush­n­er com­pa­nies, reject­ed their employ­ees’ advice. The reports were nev­er filed with the gov­ern­ment. . . .”

In addi­tion to pos­si­ble mon­ey-laun­der­ing trans­ac­tions involv­ing Trump and Kush­n­er, Deutsche Bank lent Kush­n­er $285 mil­lion the day before elec­tion day, a for­tu­itous move that allowed Kush­n­er to net $74 mil­lion on a real estate invest­ment. ” . . . . One month before Elec­tion Day, Jared Kushner’s real estate com­pa­ny final­ized a $285 mil­lion loan as part of a refi­nanc­ing pack­age for its prop­er­ty near Times Square in Man­hat­tan . . . . . . . The Deutsche Bank loan capped what Kush­n­er Cos. viewed as a tri­umph: It had pur­chased four most­ly emp­ty retail floors of the for­mer New York Times build­ing in 2015, recruit­ed ten­ants to fill the space and got the Deutsche Bank loan in a refi­nanc­ing deal that gave Kushner’s com­pa­ny $74 mil­lion more than it paid for the prop­er­ty. . . .”

Deutsche Bank does not have Trump’s tax returns, some­thing flagged by the insti­tu­tion’s employ­ees as unusu­al. The bank had pre­vi­ous­ly informed the Sec­ond Cir­cuit Court of Appeals. Note that Deutsche Bank said in a let­ter to the Unit­ed States Court of Appeals for the Sec­ond Cir­cuit in New York that they had tax returns for two mem­bers of the Trump fam­i­ly! That changed, quick­ly! “If inves­ti­ga­tors are going to get their hands on Pres­i­dent Trump’s tax returns, they will have to find them some­where oth­er than Deutsche Bank. The Ger­man bank — which for near­ly two decades was the only main­stream finan­cial insti­tu­tion con­sis­tent­ly will­ing to lend mon­ey to Mr. Trump . . . Last month, The New York Times and oth­er media out­lets asked the Unit­ed States Court of Appeals for the Sec­ond Cir­cuit in New York to unseal a let­ter from Deutsche Bank that iden­ti­fied two mem­bers of the Trump fam­i­ly whose tax returns the bank pos­sess­es. On Thurs­day, the court reject­ed the request. Part of the rea­son, it said, was that Deutsche Bank had informed the court that ‘the only tax returns it has for indi­vid­u­als and enti­ties named in the sub­poe­nas are not those of the pres­i­dent.’ Cur­rent and for­mer bank offi­cials pre­vi­ous­ly told The Times that Deutsche Bank had por­tions of Mr. Trump’s per­son­al and cor­po­rate tax returns. . . .”

An unnamed Deutsche Bank exec­u­tive not­ed in an e‑mail to the afore­men­tioned David Enrich that this was high­ly unusu­al, and the bank may have destroyed the doc­u­ments and cleansed their servers: ” . . . . David Enrich, finance edi­tor at The New York Times, post­ed to Twit­ter a screen­shot of his con­ver­sa­tion with the unnamed exec­u­tive in which they expressed sur­prise that Deutsche told a fed­er­al appeals court it did not have the president’s tax returns any­more. ‘Holy f**k,’ the exec­u­tive wrote, per the screen­shot. ‘The cir­cum­stance could be that they returned any phys­i­cal copies or destroyed any phys­i­cal copies under an agree­ment with a client and cleansed their servers. Not nor­mal though.’ . . . . ”

A dis­turb­ing per­spec­tive on the alleged “sui­cide” of Thomas Bow­ers, who was in charge of Trump’s deal­ings with the bank, as well as the alleged “sui­cide” of William Broeksmit is pro­vid­ed by an argu­ment voiced by Trump attor­ney William Consovoy in a hear­ing at the Sec­ond Cir­cuit Court of Appeals: ” . . . . [Judge] Dunne brought up Trump’s famous state­ment when he caught fire dur­ing the 2016 Repub­li­can pri­ma­ry, say­ing, ‘I could stand in the mid­dle of 5th Avenue and shoot some­body and I wouldn’t lose any vot­ers.’ ‘If he did pull out a hand­gun and shoot some­one on Fifth Ave,’ Dunne asked, ‘would the local police be restrained?‘Judge Chin raised Dunne’s point. He asked Consovoy for his ‘view on the Fifth Avenue exam­ple.’ ‘Local author­i­ties couldn’t inves­ti­gate, they couldn’t do any­thing about it?’ he asked. ‘No,’ replied a vis­i­bly annoyed Consovoy amid sti­fled chor­tles. ‘Noth­ing could be done? That’s your posi­tion?’ Chin repeat­ed. ‘That is cor­rect, that is cor­rect,’ Consovoy respond­ed . . . .”

It now appears that the Deutsche Bank case will be heard by the Supreme Court. There are already two sim­i­lar cas­es on their way to the court. It will be more than a lit­tle inter­est­ing to see how the SCOTUS rules, and how Judges Gor­such and Kavanaugh per­form in the case. ” . . . . A fed­er­al appeals court said Tues­day that Deutsche Bank must turn over detailed doc­u­ments about Pres­i­dent Trump’s finances to two con­gres­sion­al com­mit­tees, a rul­ing that will most like­ly be appealed to the Supreme Court. . . . Demo­c­ra­t­ic-con­trolled con­gres­sion­al com­mit­tees issued sub­poe­nas to two banks — Deutsche Bank, long Mr. Trump’s biggest lender, and Cap­i­tal One — this year for finan­cial records relat­ed to the pres­i­dent, his com­pa­nies and his fam­i­ly. Mr. Trump sued the banks to block them from com­ply­ing . . . . Mr. Trump’s lawyer, Jay Seku­low, said in a state­ment that ‘we are eval­u­at­ing our next options includ­ing seek­ing review at the Supreme Court of the Unit­ed States.’ He called the con­gres­sion­al sub­poe­nas ‘invalid as issued.’ . . . .”

When the Sen­ate hear­ings for Gor­such and Kavanaugh were held, none of the Sen­a­tors ques­tioned the nom­i­nees about some crit­i­cal rela­tion­ships:

Antho­ny Kennedy’s son Justin was  Trump’s  banker at Deutsche Bank. Fur­ther­more, jurists who clerked for Antho­ny Kennedy fig­ure promi­nent­ly in Trump’s judi­cial appoint­ments:

1.–” . . . . He [Trump] picked Jus­tice Neil M. Gor­such, who had served as a law clerk to Jus­tice Kennedy, to fill Jus­tice Scalia’s seat. . . .”
2.–” . . . . Then, after Jus­tice Gorsuch’s nom­i­na­tion was announced, a White House offi­cial sin­gled out two can­di­dates for the next Supreme Court vacan­cy: Judge Brett M. Kavanaugh of the Unit­ed States Court of Appeals for the Dis­trict of Colum­bia Cir­cuit and Judge Ray­mond M. Keth­ledge of the Unit­ed States Court of Appeals for the Sixth Cir­cuit, in Cincin­nati. The two judges had some­thing in com­mon: They had both clerked for Jus­tice Kennedy. . . .”
3.–” . . . . In the mean­time, as the White House turned to stock­ing the low­er courts, it did not over­look Jus­tice Kennedy’s clerks. Mr. Trump nom­i­nat­ed three of them to fed­er­al appeals courts: Judges Stephanos Bibas and Michael Scud­der, both of whom have been con­firmed, and Eric Mur­phy, the Ohio solic­i­tor gen­er­al, whom Mr. Trump nom­i­nat­ed to the Sixth Cir­cuit this month. . . .”
4.–” . . . . Jus­tice Kennedy’s son, Justin . . . . spent more than a decade at Deutsche Bank, even­tu­al­ly ris­ing to become the bank’s glob­al head of real estate cap­i­tal mar­kets, and he worked close­ly with Mr. Trump when he was a real estate devel­op­er, accord­ing to two peo­ple with knowl­edge of his role. Dur­ing Mr. Kennedy’s tenure, Deutsche Bank became Mr. Trump’s most impor­tant lender, dis­pens­ing well over $1 bil­lion in loans to him for the ren­o­va­tion and con­struc­tion of sky­scrap­ers in New York and Chica­go at a time oth­er main­stream banks were wary of doing busi­ness with him because of his trou­bled busi­ness his­to­ry. . . .”

The Justin Kennedy/Trump fam­i­ly rela­tion­ship does not end there: After Kennedy left Deutsche Bank in 2009 he went on to become co-CEO LNR Prop­er­ty LLC. LNR Prop­er­ty saved Jared Kushner’s mid­town Man­hat­tan prop­er­ty in 2011:

1.–” . . . . from 2010–2013 Justin Kennedy was the co-CEO of LNR Prop­er­ty LLC with Tobin Cobb. . . .”
2.–” . . . . Accord­ing the New York Times, in 2007 Kush­n­er Com­pa­nies pur­chased ‘an alu­minum-clad office tow­er in Mid­town Man­hat­tan, for a record price of $1.8 bil­lion.’ At the time the NYT wrote that this deal was ‘con­sid­ered a clas­sic exam­ple of reck­less under­writ­ing. The trans­ac­tion was so high­ly lever­aged that the cash flow from rents amount­ed to only 65 per­cent of the debt ser­vice.’ . . .”
3.– ” . . . Who came to the res­cue? None oth­er than LNR Prop­er­ty, the com­pa­ny whose CEO at the time was Justin Kennedy. Accord­ing to the NYT and the Real Deal, Mr. Kush­n­er and LNR ‘reached a pos­si­ble agree­ment with LNR Prop­er­ty, a firm spe­cial­iz­ing in restruc­tur­ing trou­bled debt and which over­sees the mort­gage, that would allow him to retain con­trol of the tow­er by mod­i­fy­ing the terms of the $1.2 bil­lion mort­gage tied to the office por­tion of the build­ing.’ . . .”

Last time we checked, Deutsche Bank was not a Russ­ian bank. The pro­gram con­cludes with review of infor­ma­tion from Mar­tin Bor­mann: Nazi in Exile.

Mar­tin Bor­mann: Nazi in Exile; Paul Man­ning; Copy­right 1981 [HC]; Lyle Stu­art Inc.; ISBN 0–8184-0309–8; p. 205.

. . . . The [FBI] file [on Mar­tin Bor­mann] revealed that he had been bank­ing under his own name from his office in Ger­many in Deutsche Bank of Buenos Aires since 1941; that he held one joint account with the Argen­tin­ian dic­ta­tor Juan Per­on, and on August 4, 5 and 14, 1967, had writ­ten checks on demand accounts in first Nation­al City Bank (Over­seas Divi­sion) of New York, The Chase Man­hat­tan Bank, and Man­u­fac­tur­ers Hanover Trust Co., all cleared through Deutsche Bank of Buenos Aires. . . .

Pro­gram High­lights Include: Dis­cus­sion of the alleged “sui­cide” of Calogero Gam­bi­no, a Deutsche Bank attor­ney; the fact that Antho­ny Kennedy only agreed to resign after he was assured that Brett Kavanaugh would be named as his replace­ment. 

Comedian Mort Sahl in 1976: The CIA Staffs the Left

One of sev­er­al role mod­els who inspired Mr. Emory to do his life’s work is polit­i­cal come­di­an Mort Sahl. One of Jim Gar­rison’s inves­ti­ga­tors, Sahl paid the price for his engage­ment. From an enter­tain­ment and media super­star, he became rel­e­gat­ed to the mar­gins of expo­sure and earn­ing pow­er. In his 1976 auto­bi­og­ra­phy Heart­land, he chron­i­cled some sus­pi­cious vio­lent events in New Orleans that imme­di­ate­ly pre­ced­ed Gar­rison’s cam­paign for re-elec­tion. Sahl sur­mised that this was prob­a­bly part of a CIA cam­paign to destroy Gar­ri­son. In our long series on Jim DiEu­ge­nio’s Des­tiny Betrayed, we not­ed that for­mer CIA direc­tor Richard Helms com­mit­ted the Agency to destroy­ing Gar­rison’s efforts before, dur­ing and after the tri­al of Clay Shaw. That these events may have been part of the “after” is some­thing to be care­ful­ly con­sid­ered. In his text, Sahl also notes that part of the CIA’s task is ” . . . . to staff the left. They don’t staff the right–that’ll take care of itself; they staff the left. They give a fel­low a lib­er­al cre­den­tial, they’ll let you trust him, and they’ll always give you a cook­ie. A guy writes an arti­cle for Ram­parts and says, ‘The Gulf Oil com­pa­ny wants to start a war so they can drill off­shore in Viet­nam.’ The read­er says, ‘Wow, what rev­e­la­tions.’ that’s your cook­ie. . . .”

David Sarnoff’s Axis Connection: Background to NBC and the Walter Sheridan Broadcast

In our long series of inter­views with Jim DiEu­ge­nio about his mas­ter­work “Des­tiny Betrayed,” we high­light­ed vet­er­an intel­li­gence offi­cer Wal­ter Sheri­dan’s broad­cast hatch­et job on New Orleans D.A. Jim Gar­rison’s inves­ti­ga­tion of the JFK assas­si­na­tion. The TV hit piece was broad­cast on the NBC net­work. In our dis­cus­sion of the Sheri­dan broad­cast, we not­ed the efforts of RCA chief David Sarnoff in res­ur­rect­ing the Nazi Radio France sta­tion and pre­sid­ing over its con­ver­sion to Radio Free Europe. (RCA is the par­ent com­pa­ny of NBC, which aired the Sheri­dan broad­cast.) In res­ur­rect­ing Radio France and mid­wiv­ing its con­ver­sion to Radio Free Europe, Sarnoff, who is Jew­ish, was build­ing on pro­found and trea­so­nous Axis con­nec­tions he main­tained dur­ing the war. In “Trad­ing with the Ene­my,” Charles High­am chron­i­cled the deep involve­ment of David Sarnoff with the Tran­sra­dio Con­sor­tium, which joined the Axis nations with the West­ern Allies in a telecom­mu­ni­ca­tions car­tel that pro­vid­ed vital–and lethal–intelligence to the Axis dur­ing the war. Key points of analy­sis and dis­cus­sion include: 1.–David Sarnof­f’s suc­cess­ful efforts to restore and expand the Nazi Radio France Sta­tion and re-brand it as “Radio Free Europe.” ” . . . . In 1944, Sarnoff worked for the com­plete restora­tion of the Nazi destroyed Radio France sta­tion in Paris until its sig­nal was able to reach through­out Europe. It was then reti­tled Radio Free Europe. He lat­er lob­bied the White House to expand the range and reach of Radio Free Europe. At about this point, Radio Free Europe became a pet project of Allen Dulles. Sarnoff’s com­pa­ny, Radio Cor­po­ra­tion of Amer­i­ca, became a large part of the tech­no­log­i­cal core of the NSA. . . . Robert was pres­i­dent of RCA, NBC’s par­ent com­pa­ny, at the time Sheridan’s spe­cial aired. David was chair­man. . . .” 2.–Sarnoff’s RCA was part of the Tran­sra­dio Con­sor­tium, some­thing of a broad­cast car­tel meld­ing Axis and West­ern Allied broad­cast estab­lish­ments: ” . . . . RCA was in part­ner­ship before and after Pearl Har­bor with British Cable and Wire­less; with Tele­funken, the Nazi com­pa­ny; with Ital­ca­ble, whol­ly owned by the Mus­soli­ni gov­ern­ment; and with Vichy’s Com­pag­nie Gen­erale, in an orga­ni­za­tion known as the Tran­sra­dio Con­sor­tium, with Gen­er­al Robert C. Davis, head of the New York Chap­ter of the Amer­i­can Red Cross, as its chair­man. In turn, RCA, British Cable and Wire­less, and the Ger­man and Ital­ian com­pa­nies had a share with ITT in TTP (Telegrafi­ca y Tele­fon­i­ca del Pla­ta), an Axis-con­trolled com­pa­ny pro­vid­ing tele­graph and tele­phone ser­vice between Buenos Aires and Mon­te­v­ideo. Nazis in Mon­te­v­ideo could tele­phone Buenos Aires through TTP with­out com­ing under the con­trol of either the state-owned sys­tem in Uruguay or the ITT sys­tem in Argenti­na. Mes­sages, often dan­ger­ous to Amer­i­can secu­ri­ty, were trans­mit­ted direct­ly to Berlin and Rome by Tran­sra­dio. Anoth­er share­hold­er was ITT’s Ger­man “rival,” Siemens, which linked cables and net­works with Behn south of Pana­ma. . . .” 3.–Transradio Con­sor­tium was the vehi­cle for lethal­ly trea­so­nous com­mu­ni­ca­tions dur­ing the war: ” . . . . But the pub­lic, which thought of Sarnoff as a pil­lar of patri­o­tism, would have been aston­ished to learn of his part­ner­ship with the ene­my through Tran­sra­dio and TTP. The British pub­lic, belea­guered and bombed, would have been equal­ly shocked to learn that British Cable and Wire­less, 10 per­cent owned by the British gov­ern­ment, and under vir­tu­al gov­ern­ment con­trol in wartime, was in fact also in part­ner­ship with the Ger­mans and Ital­ians through the same com­pa­nies and prox­ies. . . . Simul­ta­ne­ous­ly, the Tran­sra­dio sta­tions, accord­ing to State Depart­ment reports with the full knowl­edge of David Sarnoff, kept up a direct line to Berlin. The amount of intel­li­gence passed along the lines can scarce­ly be cal­cu­lat­ed. The Lon­don office was in con­stant touch with New York through­out the war, sift­ing through reports from Argenti­na, Brazil, and Chile and send­ing com­pa­ny reports to the Ital­ian and Ger­man inter­ests. . . .”

FTR #1058, FTR #1059 and FTR #1060 The Christian West, Parts 1, 2 and 3: Contextual Foundation of the Jim DiEugenio Interviews

Review­ing past mate­r­i­al in order to refresh and rein­force under­stand­ing of the his­tor­i­cal con­text and foun­da­tion of the recent Jim DiEu­ge­nio inter­views, this pro­gram reviews infor­ma­tion rel­e­vant to the con­cept of the Chris­t­ian West. “The Chris­t­ian West” is explained in the descrip­tion for AFA #37: ” . . . . When it became clear that the armies of the Third Reich were going to be defeat­ed, it opened secret nego­ti­a­tions with rep­re­sen­ta­tives from the West­ern Allies. Rep­re­sen­ta­tives on both sides belonged to the transat­lantic finan­cial and indus­tri­al fra­ter­ni­ty that had active­ly sup­port­ed fas­cism. The thrust of these nego­ti­a­tions was the estab­lish­ment of The Chris­t­ian West. Viewed by the Nazis as a vehi­cle for sur­viv­ing mil­i­tary defeat, ‘The Chris­t­ian West’ involved a Hitler-less Reich join­ing with the U.S., Britain, France and oth­er Euro­pean nations in a transat­lantic, pan-Euro­pean anti-Sovi­et alliance. In fact, The Chris­t­ian West became a real­i­ty only after the ces­sa­tion of hos­til­i­ties. The de-Naz­i­fi­ca­tion of Ger­many was abort­ed. Although a few of the more obvi­ous and obnox­ious ele­ments of Nazism were removed, Nazis were returned to pow­er at vir­tu­al­ly every lev­el and in almost every capac­i­ty in the Fed­er­al Repub­lic of Ger­many. . . .”

Against the back­ground of Allen and John Fos­ter Dulles’ long, over­lap­ping careers as lawyers for Sul­li­van & Cromwell, as well as gov­ern­ment oper­a­tives, we note the deci­sive role of car­tels in pre­cip­i­tat­ing fas­cism and the posi­tion in the polit­i­cal and macro-eco­nom­ic land­scape of the events stem­ming from that.

Pro­gram High­lights Include: Amer­i­can recruit­ment of Nazi East­ern Front intel­li­gence offi­cers in August of 1944 (far ear­li­er than gen­er­al­ly sup­posed); The Gehlen “Org“ ‘s incor­po­ra­tion into the CIA with the con­sent of a Nazi chain of com­mand that was still in exis­tence; the role in the Gehlen Org of East­ern Euro­pean fas­cist orga­ni­za­tions includ­ing the OUN/B, the Roman­ian Iron Guard, the Croa­t­ian Ustachi, the Bul­gar­i­an Nation­al Front and the SS Baltic Legion; the incor­po­ra­tion of those same Gehlen-con­trolled East­ern Euro­pean fas­cists into the GOP via the Cru­sade For Free­dom (CFF); the piv­otal role of Gehlen/Nazi/CFF per­son­nel in the post­war GOP (Richard Nixon, Ronald Rea­gan, William Casey and George H.W. Bush); the re-insti­tu­tion of Nazis in the “New” Fed­er­al Repub­lic of Ger­many; the con­trol of the “New” Fed­er­al Repub­lic of Ger­many by an under­ground Nazi fuehringsring and a com­mand cen­ter in Madrid; the role of Cana­di­an nick­el inter­ests in John Fos­ter Dulles’ cob­bling togeth­er of I.G. Far­ben; Gar­ri­son inves­tiga­tive tar­get Clay Shaw’s net­work­ing with Cana­di­an nick­el inter­ests; the role of both Dulles broth­ers in frus­trat­ing the inter­dic­tion of the Bor­mann flight cap­i­tal pro­gram; the [appar­ent­ly suc­cess­ful] nego­ti­a­tions between OSS chief William Dono­van, his aide Allen Dulles and rep­re­sen­ta­tive of the SS to real­ize the Chris­t­ian West con­cept; the role of Cru­sade For Free­dom per­son­nel in the assas­si­na­tion of Pres­i­dent Kennedy; Gar­ri­son inves­tiga­tive tar­get Clay Shaw’s friend­ship with Nazi Finance Min­is­ter Hjal­mar Schacht; Fos­ter Dulles’ pro­fes­sion­al inti­ma­cy with Schacht; Shaw’s links to Per­min­dex and the SS-linked Schroed­er bank­ing empire; the deci­sive role of Allen Dulles, George Her­bert Walk­er (W’s great grand­fa­ther and the grand­fa­ther of George H.W. Bush), Prescott Bush, Sr. (the father of George H.W. Bush and the grand­fa­ther of W) in laun­der­ing U.S. cap­i­tal invest­ment in Nazi Ger­many and the return of those Nazi monies to the U.S.; Nazi steel mag­nate Fritz Thyssen’s close rela­tion­ship to: Allen Dulles, Prescott Bush, Mar­tin Bor­mann and the Schroed­er bank­ing inter­ests; Allen Dulles’ “go-to” rela­tion­ship with Sen­a­tor Prescott Bush (senior) while serv­ing as head of the CIA.

FTR #1057 Miscellaneous Articles and Updates

1.–The State Depart­men­t’s “Min­istry of Truth” is going to be head­ed by a Fox News and CIA vet­er­an, Lea Gabrielle. Designed to neu­tral­ize what the Pow­ers That Be deem to be for­eign pro­pa­gan­da, the bland­ly-named Glob­al Engage­ment Cen­ter has been exem­pli­fied by its attempts to por­tray as “Russ­ian dis­in­for­ma­tion” the ver­i­fi­ably Nazi char­ac­ter and polit­i­cal her­itage of the OUN/B suc­ces­sor orga­ni­za­tions wield­ing the police, edu­ca­tion­al and nation­al secu­ri­ty reins in Ukraine. ” . . . . Gabrielle, who begins her job on Feb. 11, was described to reporters by deputy spokesman Robert Pal­ladi­no on Thurs­day as ‘a for­mer CIA-trained human intel­li­gence oper­a­tions offi­cer, defense for­eign liai­son offi­cer, Unit­ed States Navy pro­gram direc­tor, Navy F/A‑18C fight­er pilot, and nation­al tele­vi­sion news cor­re­spon­dent and anchor at two dif­fer­ent net­works. . . .”
2.–Fox News reject­ed a nation­al buy for an ad that was to run dur­ing Sean Hannity’s show. The ad pro­motes the Oscar-nom­i­nat­ed doc­u­men­tary A Night at the Gar­den, about a 1939 Nazi ral­ly in New York City. The ad includes the warn­ing “It Can Hap­pen Here” about the poten­tial dan­gers of Pres­i­dent Don­ald Trump’s brand of pop­ulism. Han­ni­ty might be the most ‘Alt-Right’ of all the Fox News per­son­al­i­ties (although he has com­pe­ti­tion). The ad nev­er got to run, and was pre­clud­ed by break­ing news cov­er­age of Trump’s ral­ly in Texas–where Trump so riled up the audi­ence against ‘the media’ that a BBC cam­era­man was vio­lent­ly attacked by some­one wear­ing a MAGA hat.
3.–The El Paso Trump ral­ly man­i­fest­ed a con­tem­po­rary iter­a­tion of “A Night at the Gar­den”. ” . . . . Trump’s ral­ly in El Paso was in sup­port of his bor­der wall. In his State of the Union address last week he claimed, false­ly, that bor­der fenc­ing that was built south of the city in 2010 trans­formed El Paso from a dan­ger­ous place into a safe one. Its Repub­li­can may­or lashed out at the pres­i­dent last week for his false­hood. El Paso’s declin­ing crime rate start­ed well before the bor­der fenc­ing was built. But Trump repeat­ed the lie Mon­day night. And for his audi­ence, the lie was now the truth. ‘Once they built that wall, it was amaz­ing how sta­tis­ti­cal­ly the vio­lence start­ed going down,’ 39-year-old El Paso res­i­dent Michael Blan­co, who owns an account­ing busi­ness, told Huff­Post out­side the col­i­se­um. ‘I’m a com­plete wit­ness of it. Seen it grow­ing up.’ Hen­ri Rafael, a 58-year-old El Pasoan wear­ing a black Trump 2020 hat, said that even though the may­or cor­rect­ed Trump, ‘I know for a fact that the crime was high back in the ’70s and ’80s, and when they built those walls, [crime] has dropped.’ In fact, vio­lent crime increased in El Paso in the two years after the wall was built, accord­ing to a study from the El Paso Times. Trump peri­od­i­cal­ly paused his speech Mon­day for chants of ‘Build the wall!’ and ‘USA!’ When he talked of the ‘fake news’ media, the crowd jeered. At one point, a par­tic­u­lar­ly inspired Trump sup­port­er attacked a BBC jour­nal­ist . . . .”
4.–Next, we have an update on Data Pro­pria, the Cam­bridge Ana­lyt­i­ca off­shoot cre­at­ed by Brad Parscale’s com­pa­ny Cloud Com­merce. The GOP hired the ser­vices of Data Pro­pria for the 2018 mid-terms. Data Pro­pria employs four ex-Cam­bridge Ana­lyt­i­ca employ­ees, includ­ing Cam­bridge Analytica’s chief data sci­en­tist. Cam­bridge Analytica’s for­mer head of prod­uct, Matt Oczkows­ki, leads Data Propia. Oczkows­ki led the Cam­bridge Ana­lyt­i­ca team that worked for Trump’s 2016 cam­paign, and was report­ed­ly over­heard brag­ging to a prospec­tive client about how he’s already work­ing on Trump’s 2020 cam­paign (which he sub­se­quent­ly denied). Brad Parscale ran the Trump 2016 campaign’s exten­sive dig­i­tal oper­a­tions that includ­ed exten­sive micro-tar­get­ing of indi­vid­u­als out­side of the Cam­bridge Ana­lyt­i­ca efforts.
5.–Matt Oczkows­ki is now the run­ning Parscale Dig­i­tal in addi­tion to Data Pro­pria. Parscale Dig­i­tal is the rebrand­ed ver­sion of Parscale’s old mar­ket­ing com­pa­ny. As the fol­low­ing arti­cle notes, Parscale sold his shares in Parscale Dig­i­tal in August 2017, at the same time he pur­chased $9 mil­lion in stock for Cloud Com­merce and took a seat on its board. August of 2017 is also the same month Parscale Dig­i­tal was sold to Cloud Com­merce. Thus, Parscale is a co-own­er of Cloud Com­merce which the own­er of Parscale Dig­i­tal. Now Matt Oczkows­ki, the for­mer head of prod­uct for Cam­bridge Ana­lyt­i­ca, is run­ning Parscale Dig­i­tal.
6.–After a mem­ber of an “antifa” group was stabbed at a white suprema­cist ral­ly, the FBI inves­ti­gat­ed the pro­test­ers, rather than the KKK. ” . . . . Fed­er­al author­i­ties ran a sur­veil­lance oper­a­tion on By Any Means Nec­es­sary (Bamn), spy­ing on the left­ist group’s move­ments in an inquiry that came after one of Bamn’s mem­bers was stabbed at the white suprema­cist ral­ly, accord­ing to doc­u­ments obtained by the Guardian. The FBI’s Bamn files reveal: * The FBI inves­ti­gat­ed Bamn for poten­tial ‘con­spir­a­cy’ against the ‘rights’ of the ‘Ku Klux Klan’ and white suprema­cists. * The FBI con­sid­ered the KKK as vic­tims and the left­ist pro­test­ers as poten­tial ter­ror threats, and down­played the threats of the Klan, writ­ing: ‘The KKK con­sist­ed of mem­bers that some per­ceived to be sup­port­ive of a white suprema­cist agen­da.’ * The FBI’s mon­i­tor­ing includ­ed in-per­son sur­veil­lance, and the agency cit­ed Bamn’s advo­ca­cy against ‘rape and sex­u­al assault’ and ‘police bru­tal­i­ty’ as evi­dence in the ter­ror­ism inquiry. The FBI’s 46-page report on Bamn, obtained by the gov­ern­ment trans­paren­cy non-prof­it Prop­er­ty of the Peo­ple through a records request, pre­sent­ed an ‘aston­ish­ing’ descrip­tion of the KKK, said Mike Ger­man, a for­mer FBI agent and far-right expert who reviewed the doc­u­ments for the Guardian. . . . ”
7.–The FBI inves­ti­ga­tion into the motive behind Stephen Paddock’s mas­sacre in Las Vegas has omit­ted Pad­dock­’s links with the Sov­er­eign Cit­i­zen move­ment, which we high­light­ed in FTR #1011. ” . . . . The high-stakes gam­bler respon­si­ble for the dead­liest mass shoot­ing in mod­ern U.S. his­to­ry sought noto­ri­ety in the attack but left his spe­cif­ic motive a mys­tery, the FBI said Tues­day as it con­clud­ed the inves­ti­ga­tion of the 2017 mas­sacre that killed 58 coun­try music fans. . . .”
8.–This soci­ety has been sow­ing the Nazi and fas­cist winds for a long time. Fail­ing to come to terms with the Nazi and fas­cist sym­pa­thies of Amer­i­can indus­tri­al­ists who financed Hitler, the incor­po­ra­tion of the Nazi SS into the CIA via the Gehlen org, and the incor­po­ra­tion of East­ern and Cen­tral Euro­pean SS-allied fas­cists into the GOP has borne its inevitable fruit. Now it will be reap­ing the Nazi whirl­wind. An extreme­ly pop­u­lar chil­dren’s lip-synch­ing app called Tik­Tok has incor­po­rat­ed mur­der­ous­ly racist invec­tive against peo­ple of col­or and Jews, in addi­tion to shar­ing overt­ly Nazi pro­pa­gan­da.
9.–Even as offi­cial­dom and the media down­play or out­right dis­miss the Junior Prom pho­to from Bara­boo High School, we should expect things to become dra­mat­i­cal­ly worse. Time grows short. Tik Tok! ” . . . . Police announced on Mon­day they were inves­ti­gat­ing after a pho­to emerged on social media show­ing dozens of pupils — most­ly 16 and 17 — from Bara­boo High School appar­ent­ly per­form­ing the ‘Sieg Heil’ greet­ing dur­ing their junior prom. One for­mer stu­dent at the school in Bara­boo, a town of around 12,000 peo­ple, said she knew some of the boys in the pho­to and that their behav­iour was ‘def­i­nite­ly not sur­pris­ing’. ‘Some of the boys in this pho­to are noto­ri­ous at our school for this kind of behav­iour,’ said the 19-year-old, who grad­u­at­ed ear­li­er this year and wished to remain anony­mous. . . .”
10.–Announced Demo­c­ra­t­ic Pres­i­den­tial can­di­date Kamala Har­ris opposed the 2012 parole bid of demon­stra­bly inno­cent Sirhan Sirhan, the pat­sy for the RFK assas­si­na­tion.
11.–With the New Cold War gath­er­ing momen­tum and Trump’s with­draw­al from the treaty on inter­me­di­ate range nuclear mis­siles point­ing the world toward war, it is worth reflect­ing on the his­to­ry and deep pol­i­tics that brought this about. Colonel L. Fletch­er Prouty has writ­ten about events in August of 1944 that are indica­tive of the coa­les­cence of the “Chris­t­ian West” con­cept that we dis­cussed in AFA #37 and fur­ther devel­oped in FTR #1009. Note that this was well before the offi­cial incor­po­ra­tion of the Gehlen “Org” into CIA. We note that it was in August of 1944 that the famous “Red House” meet­ing at which the Bor­mann flight cap­i­tal net­work real­ized under the aus­pices of Aktion Adler­flug was launched. ” . . . . On August 23, 1944, the Roma­ni­ans accept­ed Sovi­et sur­ren­der terms and in Bucharest the OSS round­ed up Nazi intel­li­gence experts and their volu­mi­nous East­ern Euro­pean intel­li­gence files and con­cealed them among a train­load of Amer­i­can POW’s who were being quick­ly evac­u­at­ed from the Balka­ns via Turkey. Once in “neu­tral” Turkey, the train con­tin­ued to a planned des­ti­na­tion at a site on the Syr­i­an bor­der, where it was stopped to per­mit the trans­fer of Nazis and POW’s to a fleet of U.S. [Army] Air Force planes for a flight to Cairo. I was the chief pilot of that flight of some thir­ty air­craft . . . . It was this covert fac­tion with­in the OSS, coor­di­nat­ed with a sim­i­lar British intel­li­gence fac­tion, and its poli­cies that encour­aged cho­sen Nazis to con­ceive of the divi­sive ‘Iron Cur­tain’ con­cept to dri­ve a wedge in the alliance with the Sovi­et Union as ear­ly as 1944–to save their own necks, to sal­vage cer­tain pow­er cen­ters and their wealth, and to stir up resent­ment against the Rus­sians, even at the time of their great­est mil­i­tary tri­umph. . . . .”